,id,cid,dsn,cmpdname,srccmpd,srccmpdname,srccmpdurl,srctarget,srctargetname,srctargeturl,protacxn,protname,geneid,genename,taxid,taxname,action,actname,actvalue,evids,evurls,pmids,dois,citations
0,1340861,83003,Toxin and Toxin Target Database (T3DB),Yttrium arsenide,T3D1292,Yttrium(III) arsenide,http://www.t3db.ca/toxins/T3D1292,BE0000123,Estrogen receptor,http://www.t3db.ca/biodb/bio_entities/BE0000123,P03372,Estrogen receptor,2099.0,ESR1,9606.0,Homo sapiens (human),Arsenic binds to the estrogen receptor. (A17),,,PMID:18164070,https://www.ncbi.nlm.nih.gov/pubmed/18164070,18164070,,
1,1417994,186907,Comparative Toxicogenomics Database (CTD),Aflatoxin B1,D016604,Aflatoxin B1,https://ctdbase.org/detail.go?type=chem&acc=D016604,1906,EDN1,https://ctdbase.org/detail.go?type=gene&acc=1906,,,1906.0,EDN1,9606.0,Homo sapiens (human),Aflatoxin B1 affects the expression of EDN1 protein,,,PMID:20106945,https://www.ncbi.nlm.nih.gov/pubmed/20106945,20106945,,
2,1963709,10220590,Therapeutic Target Database (TTD),6-Amino-4-[(3-methylphenyl)amino]quinazoline,D0X4UE,"N4-(3-methylphenyl)-4,6-quinazolinediamine",https://idrblab.net/ttd/data/drug/details/D0X4UE,T59328,Epidermal growth factor receptor (EGFR),https://idrblab.net/ttd/data/target/details/T59328,P00533,Epidermal growth factor receptor,1956.0,EGFR,9606.0,Homo sapiens (human),Inhibitor,,,,,,,
3,1963742,10246233,Therapeutic Target Database (TTD),2-Benzenesulfonamido-5-butylbenzoic acid,D09KTF,5-butyl-2-(phenylsulfonamido)benzoic acid,https://idrblab.net/ttd/data/drug/details/D09KTF,T75596,Methionine aminopeptidase 2 (METAP2),https://idrblab.net/ttd/data/target/details/T75596,P50579,Methionine aminopeptidase 2,10988.0,METAP2,9606.0,Homo sapiens (human),Inhibitor,,,,,,,
4,1963743,10247424,BindingDB,Triazolopyridine oxazole inhibitor 68,16397,"5-{3-cyclobutyl-[1,2,4]triazolo[3,4-a]pyridin-6-yl}-4-(2,5-difluorophenyl)-1,3-oxazole",https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=16397,3881,Mitogen-activated protein kinase 14,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=3881,Q16539,Mitogen-activated protein kinase 14,1432.0,MAPK14,9606.0,Homo sapiens (human),,IC50 (nM),9.7,PMID:16759861|DOI:10.1016/j.bmcl.2006.05.056,https://www.ncbi.nlm.nih.gov/pubmed/16759861|https://doi.org/10.1016/j.bmcl.2006.05.056,16759861,10.1016/j.bmcl.2006.05.056,
5,1963744,10247543,BindingDB,Triazolopyridine oxazole inhibitor 64,16393,"5-{3-tert-butyl-[1,2,4]triazolo[3,4-a]pyridin-6-yl}-4-(2,4-difluorophenyl)-1,3-oxazole",https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=16393,3881,Mitogen-activated protein kinase 14,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=3881,Q16539,Mitogen-activated protein kinase 14,1432.0,MAPK14,9606.0,Homo sapiens (human),,IC50 (nM),1.1,PMID:16759861|DOI:10.1016/j.bmcl.2006.05.056,https://www.ncbi.nlm.nih.gov/pubmed/16759861|https://doi.org/10.1016/j.bmcl.2006.05.056,16759861,10.1016/j.bmcl.2006.05.056,
6,1963745,10247610,Therapeutic Target Database (TTD),4-methoxy-N-(3-(pyridin-2-yl)isoquinolin-1-yl)benzamide,D06FNT,VUF-8504,https://idrblab.net/ttd/data/drug/details/D06FNT,T36059,Adenosine A3 receptor (ADORA3),https://idrblab.net/ttd/data/target/details/T36059,P0DMS8,Adenosine receptor A3,140.0,ADORA3,9606.0,Homo sapiens (human),Inhibitor,,,,,,,
7,1963746,10248110,Therapeutic Target Database (TTD),"(6aR,10aR)-6,6,9-Trimethyl-3-(2-phenylpropan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol",D0P5VJ,KM-233,https://idrblab.net/ttd/data/drug/details/D0P5VJ,T37693,Cannabinoid receptor 2 (CB2),https://idrblab.net/ttd/data/target/details/T37693,P34972,Cannabinoid receptor 2 ,1269.0,CNR2,9606.0,Homo sapiens (human),Inhibitor,,,,,,,
8,1963747,10248110,Therapeutic Target Database (TTD),"(6aR,10aR)-6,6,9-Trimethyl-3-(2-phenylpropan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol",D0P5VJ,KM-233,https://idrblab.net/ttd/data/drug/details/D0P5VJ,T76685,Cannabinoid receptor 1 (CB1),https://idrblab.net/ttd/data/target/details/T76685,P21554,Cannabinoid receptor 1,1268.0,CNR1,9606.0,Homo sapiens (human),Inhibitor,,,,,,,
9,1963748,10255083,Drug Gene Interaction database (DGIdb),Carminic acid,,CARMINIC ACID,https://www.dgidb.org/drugs/rxcui:1368643,,ATXN2,https://www.dgidb.org/genes/hgnc:10555,,,6311.0,ATXN2,9606.0,Homo sapiens (human),,,,,,,,
10,1963749,10255083,Drug Gene Interaction database (DGIdb),Carminic acid,,CARMINIC ACID,https://www.dgidb.org/drugs/rxcui:1368643,,L3MBTL1,https://www.dgidb.org/genes/hgnc:15905,,,26013.0,L3MBTL1,9606.0,Homo sapiens (human),,,,,,,,
11,1963750,10255083,Drug Gene Interaction database (DGIdb),Carminic acid,,CARMINIC ACID,https://www.dgidb.org/drugs/rxcui:1368643,,POLK,https://www.dgidb.org/genes/hgnc:9183,,,51426.0,POLK,9606.0,Homo sapiens (human),,,,,,,,
12,1963751,10257704,BindingDB,Methyl N-[(2s)-4-{[(1s)-1-{[(2s)-2-Carboxypyrrolidin-1-Yl]carbonyl}-3-Methylbutyl]amino}-2-Hydroxy-4-Oxobutanoyl]-L-Leucylglycylglycinate,16511,"(2S)-1-[(2S)-2-{[(2S,3S)-3-{[(1S)-1-({[(2-methoxy-2-oxoethyl)carbamoyl]methyl}carbamoyl)-3-methylbutyl]carbamoyl}oxiran-2-yl]formamido}-4-methylpentanoyl]pyrrolidine-2-carboxylic acid",https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=16511,1730,Cathepsin B,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=1730,P07688,Cathepsin B,281105.0,CTSB,9913.0,Bos taurus (cattle),,,,PMID:16950396|DOI:10.1016/j.jmb.2006.07.070,https://www.ncbi.nlm.nih.gov/pubmed/16950396|https://doi.org/10.1016/j.jmb.2006.07.070,16950396,10.1016/j.jmb.2006.07.070,
13,1964001,10316101,BindingDB,Triazolopyridine oxazole inhibitor 70,16399,"5-{3-tert-butyl-[1,2,4]triazolo[3,4-a]pyridin-6-yl}-4-(2,5-difluorophenyl)-1,3-oxazole",https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=16399,3881,Mitogen-activated protein kinase 14,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=3881,Q16539,Mitogen-activated protein kinase 14,1432.0,MAPK14,9606.0,Homo sapiens (human),,IC50 (nM),8.8,PMID:16759861|DOI:10.1016/j.bmcl.2006.05.056,https://www.ncbi.nlm.nih.gov/pubmed/16759861|https://doi.org/10.1016/j.bmcl.2006.05.056,16759861,10.1016/j.bmcl.2006.05.056,
14,1964002,10320529,BindingDB,"(2S)-2,6-diamino-1-(2-diphenoxyphosphorylpyrrolidin-1-yl)hexan-1-one",98046,"(2S)-2,6-diamino-1-(2-diphenoxyphosphorylpyrrolidin-1-yl)hexan-1-one",https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=98046,1234,Dipeptidyl peptidase 4,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=1234,P27487,Dipeptidyl peptidase 4,1803.0,DPP4,9606.0,Homo sapiens (human),,IC50 (nM),117000,PMID:12739951|DOI:10.1021/cc020096o,https://www.ncbi.nlm.nih.gov/pubmed/12739951|https://doi.org/10.1021/cc020096o,12739951,10.1021/cc020096o,
15,1964044,10331844,Comparative Toxicogenomics Database (CTD),Napabucasin,C000621033,napabucasin,https://ctdbase.org/detail.go?type=chem&acc=C000621033,3676,ITGA4,https://ctdbase.org/detail.go?type=gene&acc=3676,,,3676.0,ITGA4,9606.0,Homo sapiens (human),Napabucasin results in decreased expression of ITGA4 mRNA,,,PMID:25605917,https://www.ncbi.nlm.nih.gov/pubmed/25605917,25605917,,
16,1964045,10331844,Comparative Toxicogenomics Database (CTD),Napabucasin,C000621033,napabucasin,https://ctdbase.org/detail.go?type=chem&acc=C000621033,3655,ITGA6,https://ctdbase.org/detail.go?type=gene&acc=3655,,,3655.0,ITGA6,9606.0,Homo sapiens (human),Napabucasin results in decreased expression of ITGA6 mRNA,,,PMID:25605917,https://www.ncbi.nlm.nih.gov/pubmed/25605917,25605917,,
17,1964046,10331844,Comparative Toxicogenomics Database (CTD),Napabucasin,C000621033,napabucasin,https://ctdbase.org/detail.go?type=chem&acc=C000621033,3688,ITGB1,https://ctdbase.org/detail.go?type=gene&acc=3688,,,3688.0,ITGB1,9606.0,Homo sapiens (human),Napabucasin results in decreased expression of ITGB1 mRNA,,,PMID:25605917,https://www.ncbi.nlm.nih.gov/pubmed/25605917,25605917,,
18,1964047,10331844,Comparative Toxicogenomics Database (CTD),Napabucasin,C000621033,napabucasin,https://ctdbase.org/detail.go?type=chem&acc=C000621033,182,JAG1,https://ctdbase.org/detail.go?type=gene&acc=182,,,182.0,JAG1,9606.0,Homo sapiens (human),Napabucasin results in decreased expression of JAG1 mRNA,,,PMID:25605917,https://www.ncbi.nlm.nih.gov/pubmed/25605917,25605917,,
19,1964048,10331844,Comparative Toxicogenomics Database (CTD),Napabucasin,C000621033,napabucasin,https://ctdbase.org/detail.go?type=chem&acc=C000621033,3717,JAK2,https://ctdbase.org/detail.go?type=gene&acc=3717,,,3717.0,JAK2,9606.0,Homo sapiens (human),Napabucasin results in decreased expression of JAK2 mRNA,,,PMID:25605917,https://www.ncbi.nlm.nih.gov/pubmed/25605917,25605917,,
20,1964049,10331844,Comparative Toxicogenomics Database (CTD),Napabucasin,C000621033,napabucasin,https://ctdbase.org/detail.go?type=chem&acc=C000621033,4254,KITLG,https://ctdbase.org/detail.go?type=gene&acc=4254,,,4254.0,KITLG,9606.0,Homo sapiens (human),Napabucasin results in decreased expression of KITLG mRNA,,,PMID:25605917,https://www.ncbi.nlm.nih.gov/pubmed/25605917,25605917,,
21,1964050,10331844,Comparative Toxicogenomics Database (CTD),Napabucasin,C000621033,napabucasin,https://ctdbase.org/detail.go?type=chem&acc=C000621033,128209,KLF17,https://ctdbase.org/detail.go?type=gene&acc=128209,,,128209.0,KLF17,9606.0,Homo sapiens (human),Napabucasin results in decreased expression of KLF17 mRNA,,,PMID:25605917,https://www.ncbi.nlm.nih.gov/pubmed/25605917,25605917,,
22,1964051,10331844,Comparative Toxicogenomics Database (CTD),Napabucasin,C000621033,napabucasin,https://ctdbase.org/detail.go?type=chem&acc=C000621033,9314,KLF4,https://ctdbase.org/detail.go?type=gene&acc=9314,,,9314.0,KLF4,9606.0,Homo sapiens (human),Napabucasin results in decreased expression of KLF4 mRNA,,,PMID:26899963,https://www.ncbi.nlm.nih.gov/pubmed/26899963,26899963,,
23,1964052,10331844,Comparative Toxicogenomics Database (CTD),Napabucasin,C000621033,napabucasin,https://ctdbase.org/detail.go?type=chem&acc=C000621033,9314,KLF4,https://ctdbase.org/detail.go?type=gene&acc=9314,,,9314.0,KLF4,9606.0,Homo sapiens (human),Napabucasin results in decreased expression of KLF4 protein,,,PMID:25605917|PMID:26899963,https://www.ncbi.nlm.nih.gov/pubmed/25605917|https://www.ncbi.nlm.nih.gov/pubmed/26899963,25605917|26899963,,
24,1964073,10331844,Comparative Toxicogenomics Database (CTD),Napabucasin,C000621033,napabucasin,https://ctdbase.org/detail.go?type=chem&acc=C000621033,5329,PLAUR,https://ctdbase.org/detail.go?type=gene&acc=5329,,,5329.0,PLAUR,9606.0,Homo sapiens (human),Napabucasin results in decreased expression of PLAUR mRNA,,,PMID:25605917,https://www.ncbi.nlm.nih.gov/pubmed/25605917,25605917,,
25,1964074,10331844,Comparative Toxicogenomics Database (CTD),Napabucasin,C000621033,napabucasin,https://ctdbase.org/detail.go?type=chem&acc=C000621033,5460,POU5F1,https://ctdbase.org/detail.go?type=gene&acc=5460,,,5460.0,POU5F1,9606.0,Homo sapiens (human),Napabucasin results in decreased expression of POU5F1 mRNA,,,PMID:25605917,https://www.ncbi.nlm.nih.gov/pubmed/25605917,25605917,,
26,1964075,10331844,Comparative Toxicogenomics Database (CTD),Napabucasin,C000621033,napabucasin,https://ctdbase.org/detail.go?type=chem&acc=C000621033,6175,RPLP0,https://ctdbase.org/detail.go?type=gene&acc=6175,,,6175.0,RPLP0,9606.0,Homo sapiens (human),Napabucasin results in decreased expression of RPLP0 mRNA,,,PMID:25605917,https://www.ncbi.nlm.nih.gov/pubmed/25605917,25605917,,
27,1964076,10331844,Comparative Toxicogenomics Database (CTD),Napabucasin,C000621033,napabucasin,https://ctdbase.org/detail.go?type=chem&acc=C000621033,23411,SIRT1,https://ctdbase.org/detail.go?type=gene&acc=23411,,,23411.0,SIRT1,9606.0,Homo sapiens (human),Napabucasin results in decreased expression of SIRT1 mRNA,,,PMID:25605917,https://www.ncbi.nlm.nih.gov/pubmed/25605917,25605917,,
28,1964077,10331844,Comparative Toxicogenomics Database (CTD),Napabucasin,C000621033,napabucasin,https://ctdbase.org/detail.go?type=chem&acc=C000621033,6608,SMO,https://ctdbase.org/detail.go?type=gene&acc=6608,,,6608.0,SMO,9606.0,Homo sapiens (human),Napabucasin results in decreased expression of SMO mRNA,,,PMID:25605917,https://www.ncbi.nlm.nih.gov/pubmed/25605917,25605917,,
29,1964078,10331844,Comparative Toxicogenomics Database (CTD),Napabucasin,C000621033,napabucasin,https://ctdbase.org/detail.go?type=chem&acc=C000621033,6657,SOX2,https://ctdbase.org/detail.go?type=gene&acc=6657,,,6657.0,SOX2,9606.0,Homo sapiens (human),Napabucasin results in decreased expression of SOX2 mrna|napabucasin results in decreased expression of SOX2 protein,,,PMID:25605917,https://www.ncbi.nlm.nih.gov/pubmed/25605917,25605917,,
30,1964079,10331844,Comparative Toxicogenomics Database (CTD),Napabucasin,C000621033,napabucasin,https://ctdbase.org/detail.go?type=chem&acc=C000621033,6774,STAT3,https://ctdbase.org/detail.go?type=gene&acc=6774,,,6774.0,STAT3,9606.0,Homo sapiens (human),Napabucasin results in decreased expression of STAT3 mRNA,,,PMID:25605917,https://www.ncbi.nlm.nih.gov/pubmed/25605917,25605917,,
31,1964115,10337743,Therapeutic Target Database (TTD),"3-((3-Fluorophenyl)sulfonyl)-N,N-dimethyl-1H-pyrrolo(2,3-b)pyridine-1-ethanamine",D0OG0R,WAY-208466,https://idrblab.net/ttd/data/drug/details/D0OG0R,T79062,5-HT 7 receptor (HTR7),https://idrblab.net/ttd/data/target/details/T79062,P34969,5-hydroxytryptamine receptor 7,3363.0,HTR7,9606.0,Homo sapiens (human),Inhibitor,,,,,,,
32,1964116,10337743,Therapeutic Target Database (TTD),"3-((3-Fluorophenyl)sulfonyl)-N,N-dimethyl-1H-pyrrolo(2,3-b)pyridine-1-ethanamine",D0OG0R,WAY-208466,https://idrblab.net/ttd/data/drug/details/D0OG0R,T67162,Dopamine D2 receptor (D2R),https://idrblab.net/ttd/data/target/details/T67162,P14416,D(2) dopamine receptor,1813.0,DRD2,9606.0,Homo sapiens (human),Inhibitor,,,,,,,
33,1964117,10337743,Therapeutic Target Database (TTD),"3-((3-Fluorophenyl)sulfonyl)-N,N-dimethyl-1H-pyrrolo(2,3-b)pyridine-1-ethanamine",D0OG0R,WAY-208466,https://idrblab.net/ttd/data/drug/details/D0OG0R,T32060,5-HT 2A receptor (HTR2A),https://idrblab.net/ttd/data/target/details/T32060,P28223,5-hydroxytryptamine receptor 2A,3356.0,HTR2A,9606.0,Homo sapiens (human),Inhibitor,,,,,,,
34,1964118,10337743,Therapeutic Target Database (TTD),"3-((3-Fluorophenyl)sulfonyl)-N,N-dimethyl-1H-pyrrolo(2,3-b)pyridine-1-ethanamine",D0OG0R,WAY-208466,https://idrblab.net/ttd/data/drug/details/D0OG0R,T16691,5-HT 6 receptor (HTR6),https://idrblab.net/ttd/data/target/details/T16691,P50406,5-hydroxytryptamine receptor 6,3362.0,HTR6,9606.0,Homo sapiens (human),Inhibitor,,,,,,,
35,1964119,10337743,Therapeutic Target Database (TTD),"3-((3-Fluorophenyl)sulfonyl)-N,N-dimethyl-1H-pyrrolo(2,3-b)pyridine-1-ethanamine",D0OG0R,WAY-208466,https://idrblab.net/ttd/data/drug/details/D0OG0R,T83813,5-HT 2C receptor (HTR2C),https://idrblab.net/ttd/data/target/details/T83813,P28335,5-hydroxytryptamine receptor 2C,3358.0,HTR2C,9606.0,Homo sapiens (human),Inhibitor,,,,,,,
36,1964120,10341154,Drug Gene Interaction database (DGIdb),VX-702,,VX-702,https://www.dgidb.org/drugs/drugbank:DB05470,,PRKD3,https://www.dgidb.org/genes/hgnc:9408,,,23683.0,PRKD3,9606.0,Homo sapiens (human),,,,,,,,
37,1964160,10382483,Comparative Toxicogenomics Database (CTD),15-Acetyldeoxynivalenol,C046760,15-acetyldeoxynivalenol,https://ctdbase.org/detail.go?type=chem&acc=C046760,92162,TMEM88,https://ctdbase.org/detail.go?type=gene&acc=92162,,,92162.0,TMEM88,9606.0,Homo sapiens (human),15-acetyldeoxynivalenol results in increased expression of TMEM88 mRNA,,,PMID:23792671,https://www.ncbi.nlm.nih.gov/pubmed/23792671,23792671,,
38,1964161,10382483,Comparative Toxicogenomics Database (CTD),15-Acetyldeoxynivalenol,C046760,15-acetyldeoxynivalenol,https://ctdbase.org/detail.go?type=chem&acc=C046760,7124,TNF,https://ctdbase.org/detail.go?type=gene&acc=7124,,,7124.0,TNF,9606.0,Homo sapiens (human),15-acetyldeoxynivalenol results in increased expression of TNF mRNA,,,PMID:23792671,https://www.ncbi.nlm.nih.gov/pubmed/23792671,23792671,,
39,1964162,10382483,Comparative Toxicogenomics Database (CTD),15-Acetyldeoxynivalenol,C046760,15-acetyldeoxynivalenol,https://ctdbase.org/detail.go?type=chem&acc=C046760,7124,TNF,https://ctdbase.org/detail.go?type=gene&acc=7124,,,7124.0,TNF,10090.0,Mus musculus (house mouse),15-acetyldeoxynivalenol results in increased expression of TNF mRNA,,,PMID:24793808,https://www.ncbi.nlm.nih.gov/pubmed/24793808,24793808,,
40,1964163,10382483,Comparative Toxicogenomics Database (CTD),15-Acetyldeoxynivalenol,C046760,15-acetyldeoxynivalenol,https://ctdbase.org/detail.go?type=chem&acc=C046760,6354,CCL7,https://ctdbase.org/detail.go?type=gene&acc=6354,,,6354.0,CCL7,10090.0,Mus musculus (house mouse),15-acetyldeoxynivalenol results in increased expression of CCL7 mRNA,,,PMID:24793808,https://www.ncbi.nlm.nih.gov/pubmed/24793808,24793808,,
41,1964164,10382483,Comparative Toxicogenomics Database (CTD),15-Acetyldeoxynivalenol,C046760,15-acetyldeoxynivalenol,https://ctdbase.org/detail.go?type=chem&acc=C046760,6351,CCL4,https://ctdbase.org/detail.go?type=gene&acc=6351,,,6351.0,CCL4,9606.0,Homo sapiens (human),15-acetyldeoxynivalenol results in increased expression of CCL4 mRNA,,,PMID:23792671,https://www.ncbi.nlm.nih.gov/pubmed/23792671,23792671,,
42,1964165,10382483,Comparative Toxicogenomics Database (CTD),15-Acetyldeoxynivalenol,C046760,15-acetyldeoxynivalenol,https://ctdbase.org/detail.go?type=chem&acc=C046760,142913,CFL1P1,https://ctdbase.org/detail.go?type=gene&acc=142913,,,142913.0,CFL1P1,9606.0,Homo sapiens (human),15-acetyldeoxynivalenol results in increased expression of CFL1P1 mRNA,,,PMID:23792671,https://www.ncbi.nlm.nih.gov/pubmed/23792671,23792671,,
43,1964166,10382483,Comparative Toxicogenomics Database (CTD),15-Acetyldeoxynivalenol,C046760,15-acetyldeoxynivalenol,https://ctdbase.org/detail.go?type=chem&acc=C046760,1390,CREM,https://ctdbase.org/detail.go?type=gene&acc=1390,,,1390.0,CREM,9606.0,Homo sapiens (human),15-acetyldeoxynivalenol results in increased expression of CREM mRNA,,,PMID:23792671,https://www.ncbi.nlm.nih.gov/pubmed/23792671,23792671,,
44,1964167,10382483,Comparative Toxicogenomics Database (CTD),15-Acetyldeoxynivalenol,C046760,15-acetyldeoxynivalenol,https://ctdbase.org/detail.go?type=chem&acc=C046760,1236,CCR7,https://ctdbase.org/detail.go?type=gene&acc=1236,,,1236.0,CCR7,9606.0,Homo sapiens (human),15-acetyldeoxynivalenol results in increased expression of CCR7 mRNA,,,PMID:23792671,https://www.ncbi.nlm.nih.gov/pubmed/23792671,23792671,,
45,1964168,10382483,Comparative Toxicogenomics Database (CTD),15-Acetyldeoxynivalenol,C046760,15-acetyldeoxynivalenol,https://ctdbase.org/detail.go?type=chem&acc=C046760,27289,RND1,https://ctdbase.org/detail.go?type=gene&acc=27289,,,27289.0,RND1,9606.0,Homo sapiens (human),15-acetyldeoxynivalenol results in increased expression of RND1 mRNA,,,PMID:23792671,https://www.ncbi.nlm.nih.gov/pubmed/23792671,23792671,,
46,1964169,10384072,Drug Gene Interaction database (DGIdb),Wee1 Inhibitor,,CHEMBL:CHEMBL379975,https://www.dgidb.org/drugs/chembl:CHEMBL379975,,MAP4K2,https://www.dgidb.org/genes/hgnc:6864,,,5871.0,MAP4K2,9606.0,Homo sapiens (human),,,,,,,,
47,1964170,10384072,Drug Gene Interaction database (DGIdb),Wee1 Inhibitor,,CHEMBL:CHEMBL379975,https://www.dgidb.org/drugs/chembl:CHEMBL379975,,TYRO3,https://www.dgidb.org/genes/hgnc:12446,,,7301.0,TYRO3,9606.0,Homo sapiens (human),,,,,,,,
48,1964171,10384508,BindingDB,Triazolopyridine oxazole inhibitor 72,16401,"5-[3-(1-methylcyclopropyl)-[1,2,4]triazolo[3,4-a]pyridin-6-yl]-4-(2,4,5-trifluorophenyl)-1,3-oxazole",https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=16401,3881,Mitogen-activated protein kinase 14,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=3881,Q16539,Mitogen-activated protein kinase 14,1432.0,MAPK14,9606.0,Homo sapiens (human),,IC50 (nM),2.3,PMID:16759861|DOI:10.1016/j.bmcl.2006.05.056,https://www.ncbi.nlm.nih.gov/pubmed/16759861|https://doi.org/10.1016/j.bmcl.2006.05.056,16759861,10.1016/j.bmcl.2006.05.056,
49,1964172,10389213,IUPHAR/BPS Guide to PHARMACOLOGY,N-[(2R)-1-[4-[3-[4-(cyclopropanecarbonyl)phenoxy]propyl]piperazin-1-yl]-1-oxopropan-2-yl]furan-2-carboxamide,1216,A-317920,https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1216,262,H1 receptor,https://guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=262,P35367,Histamine H1 receptor,3269.0,HRH1,9606.0,Homo sapiens (human),Antagonist,pKi,5.4,PMID:12606603|PMID:15294456,https://www.ncbi.nlm.nih.gov/pubmed/12606603|https://www.ncbi.nlm.nih.gov/pubmed/15294456,12606603|15294456,,
50,1964173,10389213,IUPHAR/BPS Guide to PHARMACOLOGY,N-[(2R)-1-[4-[3-[4-(cyclopropanecarbonyl)phenoxy]propyl]piperazin-1-yl]-1-oxopropan-2-yl]furan-2-carboxamide,1216,A-317920,https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1216,264,H3 receptor,https://guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=264,Q9Y5N1,Histamine H3 receptor,11255.0,HRH3,9606.0,Homo sapiens (human),Antagonist,pKi,7,PMID:12606603|PMID:15294456,https://www.ncbi.nlm.nih.gov/pubmed/12606603|https://www.ncbi.nlm.nih.gov/pubmed/15294456,12606603|15294456,,
51,1964174,10389213,IUPHAR/BPS Guide to PHARMACOLOGY,N-[(2R)-1-[4-[3-[4-(cyclopropanecarbonyl)phenoxy]propyl]piperazin-1-yl]-1-oxopropan-2-yl]furan-2-carboxamide,1216,A-317920,https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1216,264,H3 receptor,https://guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=264,Q9QYN8,Histamine H3 receptor,85268.0,Hrh3,10116.0,Rattus norvegicus (Norway rat),Antagonist,pKi,9.2,PMID:12606603|PMID:15294456,https://www.ncbi.nlm.nih.gov/pubmed/12606603|https://www.ncbi.nlm.nih.gov/pubmed/15294456,12606603|15294456,,
52,1964175,10391273,Therapeutic Target Database (TTD),sideroxylonal A,D0WX7S,SIDEROXYLONAL A,https://idrblab.net/ttd/data/drug/details/D0WX7S,T15556,Endothelial plasminogen activator inhibitor (SERPINE1),https://idrblab.net/ttd/data/target/details/T15556,P05121,Plasminogen activator inhibitor 1,5054.0,SERPINE1,9606.0,Homo sapiens (human),Inhibitor,,,,,,,
53,1964176,10393120,Therapeutic Target Database (TTD),6-hydroxymanzamine A,D05GIC,Manzamine Y,https://idrblab.net/ttd/data/drug/details/D05GIC,T70977,Glycogen synthase kinase-3 beta (GSK-3B),https://idrblab.net/ttd/data/target/details/T70977,P49841,Glycogen synthase kinase-3 beta,2932.0,GSK3B,9606.0,Homo sapiens (human),Inhibitor,,,,,,,
54,1964177,10393187,BindingDB,"dibenzyl ((2S,3R,4R,5S)-3,4-dihydroxy-1,6-diphenylhexane-2,5-diyl)dicarbamate",429412,"med.21724, Compound 85",https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=429412,4753,Replicase polyprotein 1ab,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=4753,P0C6X7,Replicase polyprotein 1ab,1489680.0,ORF1ab,694009.0,Severe acute respiratory syndrome-related coronavirus,,Ki (nM),600,PMID:32852058|DOI:10.1002/med.21724,https://www.ncbi.nlm.nih.gov/pubmed/32852058|https://doi.org/10.1002/med.21724,32852058,10.1002/med.21724,
55,1963903,10394861,Drug Gene Interaction database (DGIdb),"(E)-3-(6-acetamidopyridin-3-yl)-N-[2-[[2,4-dichloro-3-[[2-methoxy-1-(pyridin-2-ylmethyl)benzimidazol-4-yl]oxymethyl]phenyl]-methylamino]-2-oxoethyl]prop-2-enamide",,EICOSATETRANOIC ACID,https://www.dgidb.org/drugs/iuphar.ligand:2669,,POLK,https://www.dgidb.org/genes/hgnc:9183,,,51426.0,POLK,9606.0,Homo sapiens (human),,,,,,,,
56,1963904,10394861,Drug Gene Interaction database (DGIdb),"(E)-3-(6-acetamidopyridin-3-yl)-N-[2-[[2,4-dichloro-3-[[2-methoxy-1-(pyridin-2-ylmethyl)benzimidazol-4-yl]oxymethyl]phenyl]-methylamino]-2-oxoethyl]prop-2-enamide",,EICOSATETRANOIC ACID,https://www.dgidb.org/drugs/iuphar.ligand:2669,,KAT2A,https://www.dgidb.org/genes/hgnc:4201,,,2648.0,KAT2A,9606.0,Homo sapiens (human),,,,,,,,
57,1963905,10394861,Drug Gene Interaction database (DGIdb),"(E)-3-(6-acetamidopyridin-3-yl)-N-[2-[[2,4-dichloro-3-[[2-methoxy-1-(pyridin-2-ylmethyl)benzimidazol-4-yl]oxymethyl]phenyl]-methylamino]-2-oxoethyl]prop-2-enamide",,EICOSATETRANOIC ACID,https://www.dgidb.org/drugs/iuphar.ligand:2669,,ADAMTSL4-AS1,https://www.dgidb.org/genes/hgnc:32041,,,574406.0,ADAMTSL4-AS1,9606.0,Homo sapiens (human),,,,,,,,
58,1964178,10394861,Drug Gene Interaction database (DGIdb),"(E)-3-(6-acetamidopyridin-3-yl)-N-[2-[[2,4-dichloro-3-[[2-methoxy-1-(pyridin-2-ylmethyl)benzimidazol-4-yl]oxymethyl]phenyl]-methylamino]-2-oxoethyl]prop-2-enamide",,BMS-345541,https://www.dgidb.org/drugs/iuphar.ligand:5669,,PRKD2,https://www.dgidb.org/genes/hgnc:17293,,,25865.0,PRKD2,9606.0,Homo sapiens (human),,,,,,,,
59,1964179,10396050,BindingDB,"(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30R,32S,35R)-1,18-dihydroxy-12-[(2R)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl]-19-methoxy-15,17,21,23,29,35-hexamethyl-30-methylsulfanyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone",36612,"Rapamycin C-7, analog 6a",https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=36612,2391,Peptidyl-prolyl cis-trans isomerase FKBP1A,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=2391,P62942,Peptidyl-prolyl cis-trans isomerase FKBP1A,2280.0,FKBP1A,9606.0,Homo sapiens (human),,Ki (nM),1,PMID:9383449|DOI:10.1016/1074-5521(95)90264-3,https://www.ncbi.nlm.nih.gov/pubmed/9383449|https://doi.org/10.1016/1074-5521(95)90264-3,9383449,10.1016/1074-5521(95)90264-3,
60,1963906,10398360,IUPHAR/BPS Guide to PHARMACOLOGY,3-Matida,3396,3-MATIDA,https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3396,289,mGlu1 receptor,https://guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=289,P23385,Metabotropic glutamate receptor 1,24414.0,Grm1,10116.0,Rattus norvegicus (Norway rat),Antagonist,pIC50,5.2,PMID:12015200,https://www.ncbi.nlm.nih.gov/pubmed/12015200,12015200,,
61,1963907,10399068,BindingDB,"9-Amino-6-chloro-1,2,3,4-tetrahydro-acridine",8987,"6-chloro-1,2,3,4-tetrahydroacridin-9-amine",https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=8987,3619,Acetylcholinesterase,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=3619,P22303,Acetylcholinesterase,43.0,ACHE,9606.0,Homo sapiens (human),,IC50 (nM),8.32,PMID:19663388|DOI:10.1021/jm900859q,https://www.ncbi.nlm.nih.gov/pubmed/19663388|https://doi.org/10.1021/jm900859q,19663388,10.1021/jm900859q,
62,1963908,10399068,BindingDB,"9-Amino-6-chloro-1,2,3,4-tetrahydro-acridine",8987,"6-chloro-1,2,3,4-tetrahydroacridin-9-amine",https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=8987,3620,Cholinesterase,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=3620,P06276,Cholinesterase,590.0,BCHE,9606.0,Homo sapiens (human),,IC50 (nM),916,PMID:19663388|DOI:10.1021/jm900859q,https://www.ncbi.nlm.nih.gov/pubmed/19663388|https://doi.org/10.1021/jm900859q,19663388,10.1021/jm900859q,
63,1963909,10399068,BindingDB,"9-Amino-6-chloro-1,2,3,4-tetrahydro-acridine",8987,"6-chloro-1,2,3,4-tetrahydroacridin-9-amine",https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=8987,1045,Acetylcholinesterase,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=1045,P23795,Acetylcholinesterase ,540446.0,ACHE,9913.0,Bos taurus (cattle),,IC50 (nM),5.73,PMID:19663388|DOI:10.1021/jm900859q,https://www.ncbi.nlm.nih.gov/pubmed/19663388|https://doi.org/10.1021/jm900859q,19663388,10.1021/jm900859q,
64,1964209,10423722,BindingDB,6-methyl-2-oxo-N-phenyl-2H-chromene-3-carboxamide,23538,"3-Carboxamide-coumarin deriv., 20",https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=23538,336,Plasma kallikrein,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=336,P03952,Plasma kallikrein,3818.0,KLKB1,9606.0,Homo sapiens (human),,IC50 (nM),>50000,PMID:18459730|DOI:10.1021/jm8002697,https://www.ncbi.nlm.nih.gov/pubmed/18459730|https://doi.org/10.1021/jm8002697,18459730,10.1021/jm8002697,
65,1964210,10425576,Therapeutic Target Database (TTD),2-(4-Nitrophenyl)-5-(4-methoxyphenyl)thiophene,D0H0AT,2-(4-nitrophenyl)-5-(4-methoxyphenyl)thiophene,https://idrblab.net/ttd/data/drug/details/D0H0AT,T87024,Amyloid beta A4 protein (APP),https://idrblab.net/ttd/data/target/details/T87024,P05067,Amyloid-beta precursor protein,351.0,APP,9606.0,Homo sapiens (human),Inhibitor,,,,,,,
66,1964211,10427648,Therapeutic Target Database (TTD),2-[(4-Fluorobenzene)sulfonamido]naphthalene-1-carboxylic acid,D0R4KE,2-(4-fluorophenylsulfonamido)-1-naphthoic acid,https://idrblab.net/ttd/data/drug/details/D0R4KE,T75596,Methionine aminopeptidase 2 (METAP2),https://idrblab.net/ttd/data/target/details/T75596,P50579,Methionine aminopeptidase 2,10988.0,METAP2,9606.0,Homo sapiens (human),Inhibitor,,,,,,,
67,1964212,10429242,Drug Gene Interaction database (DGIdb),Mitoglitazone,,MITOGLITAZONE,https://www.dgidb.org/drugs/drugbank:DB11721,,INSR,https://www.dgidb.org/genes/hgnc:6091,,,3643.0,INSR,9606.0,Homo sapiens (human),,,,,,,,
68,1964213,10430549,IUPHAR/BPS Guide to PHARMACOLOGY,Merck SIP Agonist,2929,compound 26 [PMID: 16190743],https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2929,275,S1P1 receptor,https://guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=275,P21453,Sphingosine 1-phosphate receptor 1,1901.0,S1PR1,9606.0,Homo sapiens (human),Agonist,pIC50,9.22,PMID:16190743,https://www.ncbi.nlm.nih.gov/pubmed/16190743,16190743,,
69,1964214,10432806,BindingDB,"5-chloro-2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazo[4,5-b]pyridine",36638,L-158-678,https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=36638,4429,Beta-lactamase,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=4429,,,,,,,,IC50 (nM),3.5e+3,PMID:9545432|DOI:10.1016/s1074-5521(98)90632-9,https://www.ncbi.nlm.nih.gov/pubmed/9545432|https://doi.org/10.1016/s1074-5521(98)90632-9,9545432,10.1016/s1074-5521(98)90632-9,
70,1964215,10432806,BindingDB,"5-chloro-2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazo[4,5-b]pyridine",36638,L-158-678,https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=36638,4430,Dipeptidase 1,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=4430,P16444,Dipeptidase 1,1800.0,DPEP1,9606.0,Homo sapiens (human),,IC50 (nM),2.40e+5,PMID:9545432|DOI:10.1016/s1074-5521(98)90632-9,https://www.ncbi.nlm.nih.gov/pubmed/9545432|https://doi.org/10.1016/s1074-5521(98)90632-9,9545432,10.1016/s1074-5521(98)90632-9,
71,1964216,10437018,Drug Gene Interaction database (DGIdb),"(S)-Morpholin-3-ylmethyl (4-((1-(3-fluorobenzyl)-1H-indazol-5-yl)amino)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl)carbamate",,PAN-HER KINASE INHIBITOR AC480,https://www.dgidb.org/drugs/ncit:C48380,,ERBB2,https://www.dgidb.org/genes/hgnc:3430,,,2064.0,ERBB2,9606.0,Homo sapiens (human),,,,,,,,
72,1964217,10438479,IUPHAR/BPS Guide to PHARMACOLOGY,3-[(3-carboxycyclohexyl)carbamoyl]-4-[3-[4-(4-cyclohexyloxybutoxy)phenyl]propoxy]benzoic Acid,6197,HAMI3379,https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6197,270,CysLT2 receptor,https://guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=270,Q9NS75,Cysteinyl leukotriene receptor 2,57105.0,CYSLTR2,9606.0,Homo sapiens (human),Antagonist,pIC50,7.42,PMID:20423349,https://www.ncbi.nlm.nih.gov/pubmed/20423349,20423349,,
73,1964218,10438479,IUPHAR/BPS Guide to PHARMACOLOGY,3-[(3-carboxycyclohexyl)carbamoyl]-4-[3-[4-(4-cyclohexyloxybutoxy)phenyl]propoxy]benzoic Acid,6197,HAMI3379,https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6197,270,CysLT2 receptor,https://guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=270,Q9NS75,Cysteinyl leukotriene receptor 2,57105.0,CYSLTR2,9606.0,Homo sapiens (human),Antagonist,pIC50,8.36 - 8.42,PMID:20423349,https://www.ncbi.nlm.nih.gov/pubmed/20423349,20423349,,
74,1964278,10459196,Drug Gene Interaction database (DGIdb),"5,7-Dihydroxy-2-(4-Hydroxyphenyl)-4-Oxo-4h-Chromen-3-Yl 3,4-Di-O-Acetyl-6-Deoxy-Alpha-L-Mannopyranoside",,CHEMBL:CHEMBL240954,https://www.dgidb.org/drugs/chembl:CHEMBL240954,,RPS6KA1,https://www.dgidb.org/genes/hgnc:10430,,,6195.0,RPS6KA1,9606.0,Homo sapiens (human),,,,,,,,
75,1964279,10462426,Therapeutic Target Database (TTD),CID 10462426,D05JSY,MCL-145,https://idrblab.net/ttd/data/drug/details/D05JSY,T60693,Opioid receptor kappa (OPRK1),https://idrblab.net/ttd/data/target/details/T60693,P41145,Kappa-type opioid receptor,4986.0,OPRK1,9606.0,Homo sapiens (human),Inhibitor,,,,,,,
76,1964280,10462426,Therapeutic Target Database (TTD),CID 10462426,D05JSY,MCL-145,https://idrblab.net/ttd/data/drug/details/D05JSY,T58992,Opioid receptor delta (OPRD1),https://idrblab.net/ttd/data/target/details/T58992,P41143,Delta-type opioid receptor,4985.0,OPRD1,9606.0,Homo sapiens (human),Inhibitor,,,,,,,
77,1964281,10462426,Therapeutic Target Database (TTD),CID 10462426,D05JSY,MCL-145,https://idrblab.net/ttd/data/drug/details/D05JSY,T47768,Opioid receptor mu (MOP),https://idrblab.net/ttd/data/target/details/T47768,P35372,Mu-type opioid receptor,4988.0,OPRM1,9606.0,Homo sapiens (human),Inhibitor,,,,,,,
78,1964282,10463451,BindingDB,"(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,32S,35R)-1,18-dihydroxy-12-[(2R)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl]-19-methoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20,30-hexone",36624,"Rapamycin C-7, analog 13",https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=36624,2391,Peptidyl-prolyl cis-trans isomerase FKBP1A,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=2391,P62942,Peptidyl-prolyl cis-trans isomerase FKBP1A,2280.0,FKBP1A,9606.0,Homo sapiens (human),,Ki (nM),29,PMID:9383449|DOI:10.1016/1074-5521(95)90264-3,https://www.ncbi.nlm.nih.gov/pubmed/9383449|https://doi.org/10.1016/1074-5521(95)90264-3,9383449,10.1016/1074-5521(95)90264-3,
79,1964283,10466809,BindingDB,2-(1H-imidazol-2-ylmethyl)-1H-benzimidazole-6-carboximidamide,16305,"2-(1H-imidazol-2-ylmethyl)-1H-1,3-benzodiazole-6-carboximidamide",https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=16305,1529,Serine protease 1,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=1529,P07477,Trypsin-1,5644.0,PRSS1,9606.0,Homo sapiens (human),,Ki (nM),666,PMID:9468142|DOI:10.1038/35422,https://www.ncbi.nlm.nih.gov/pubmed/9468142|https://doi.org/10.1038/35422,9468142,10.1038/35422,
80,1964284,10466809,BindingDB,2-(1H-imidazol-2-ylmethyl)-1H-benzimidazole-6-carboximidamide,16305,"2-(1H-imidazol-2-ylmethyl)-1H-1,3-benzodiazole-6-carboximidamide",https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=16305,50000974,Tryptase beta-2,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=50000974,P20231,Tryptase beta-2,64499.0,TPSB2,9606.0,Homo sapiens (human),,Ki (nM),1650,PMID:9468142|DOI:10.1038/35422,https://www.ncbi.nlm.nih.gov/pubmed/9468142|https://doi.org/10.1038/35422,9468142,10.1038/35422,
81,1964285,10466809,BindingDB,2-(1H-imidazol-2-ylmethyl)-1H-benzimidazole-6-carboximidamide,16305,"2-(1H-imidazol-2-ylmethyl)-1H-1,3-benzodiazole-6-carboximidamide",https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=16305,334,Prothrombin,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=334,P00734,Prothrombin,2147.0,F2,9606.0,Homo sapiens (human),,Ki (nM),23.1,PMID:9468142|DOI:10.1038/35422,https://www.ncbi.nlm.nih.gov/pubmed/9468142|https://doi.org/10.1038/35422,9468142,10.1038/35422,
82,1964286,10466809,BindingDB,2-(1H-imidazol-2-ylmethyl)-1H-benzimidazole-6-carboximidamide,16305,"2-(1H-imidazol-2-ylmethyl)-1H-1,3-benzodiazole-6-carboximidamide",https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=16305,1529,Serine protease 1,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=1529,P07477,Trypsin-1,5644.0,PRSS1,9606.0,Homo sapiens (human),,Ki (nM),273000,PMID:9468142|DOI:10.1038/35422,https://www.ncbi.nlm.nih.gov/pubmed/9468142|https://doi.org/10.1038/35422,9468142,10.1038/35422,
83,1964287,10466809,BindingDB,2-(1H-imidazol-2-ylmethyl)-1H-benzimidazole-6-carboximidamide,16305,"2-(1H-imidazol-2-ylmethyl)-1H-1,3-benzodiazole-6-carboximidamide",https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=16305,50000974,Tryptase beta-2,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=50000974,P20231,Tryptase beta-2,64499.0,TPSB2,9606.0,Homo sapiens (human),,Ki (nM),28800,PMID:9468142|DOI:10.1038/35422,https://www.ncbi.nlm.nih.gov/pubmed/9468142|https://doi.org/10.1038/35422,9468142,10.1038/35422,
84,1964288,10466809,BindingDB,2-(1H-imidazol-2-ylmethyl)-1H-benzimidazole-6-carboximidamide,16305,"2-(1H-imidazol-2-ylmethyl)-1H-1,3-benzodiazole-6-carboximidamide",https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=16305,334,Prothrombin,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=334,P00734,Prothrombin,2147.0,F2,9606.0,Homo sapiens (human),,Ki (nM),15300,PMID:9468142|DOI:10.1038/35422,https://www.ncbi.nlm.nih.gov/pubmed/9468142|https://doi.org/10.1038/35422,9468142,10.1038/35422,
85,1963953,10473280,Therapeutic Target Database (TTD),1-Benzhydryl-3-(isoquinolin-5-yl)urea,D0SH1L,1-benzhydryl-3-(isoquinolin-5-yl)urea,https://idrblab.net/ttd/data/drug/details/D0SH1L,T83193,Transient receptor potential cation channel V1 (TRPV1),https://idrblab.net/ttd/data/target/details/T83193,Q8NER1,Transient receptor potential cation channel subfamily V member 1,7442.0,TRPV1,9606.0,Homo sapiens (human),Inhibitor,,,,,,,
86,1963954,10479047,BindingDB,,14863,"({3-[3-(5-carbamimidoyl-1H-1,3-benzodiazol-2-yl)-2-hydroxyphenyl]-4-hydroxyphenyl}methyl)urea",https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=14863,1341,Coagulation factor X,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=1341,P00742,Coagulation factor X,2159.0,F10,9606.0,Homo sapiens (human),,Ki (nM),2700,PMID:16621549|DOI:10.1016/j.bmcl.2006.03.049,https://www.ncbi.nlm.nih.gov/pubmed/16621549|https://doi.org/10.1016/j.bmcl.2006.03.049,16621549,10.1016/j.bmcl.2006.03.049,
87,1963955,10479047,BindingDB,,14863,"({3-[3-(5-carbamimidoyl-1H-1,3-benzodiazol-2-yl)-2-hydroxyphenyl]-4-hydroxyphenyl}methyl)urea",https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=14863,334,Prothrombin,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=334,P00734,Prothrombin,2147.0,F2,9606.0,Homo sapiens (human),,Ki (nM),90000,PMID:16621549|DOI:10.1016/j.bmcl.2006.03.049,https://www.ncbi.nlm.nih.gov/pubmed/16621549|https://doi.org/10.1016/j.bmcl.2006.03.049,16621549,10.1016/j.bmcl.2006.03.049,
88,1963956,10479047,BindingDB,,14863,"({3-[3-(5-carbamimidoyl-1H-1,3-benzodiazol-2-yl)-2-hydroxyphenyl]-4-hydroxyphenyl}methyl)urea",https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=14863,1346,Coagulation factor VII,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=1346,P08709,Coagulation factor VII,2155.0,F7,9606.0,Homo sapiens (human),,Ki (nM),13,PMID:16621549|DOI:10.1016/j.bmcl.2006.03.049,https://www.ncbi.nlm.nih.gov/pubmed/16621549|https://doi.org/10.1016/j.bmcl.2006.03.049,16621549,10.1016/j.bmcl.2006.03.049,
89,1963957,10479047,BindingDB,,14863,"({3-[3-(5-carbamimidoyl-1H-1,3-benzodiazol-2-yl)-2-hydroxyphenyl]-4-hydroxyphenyl}methyl)urea",https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=14863,177,Serine protease 1,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=177,P00760,Cationic trypsin,615026.0,LOC615026,9913.0,Bos taurus (cattle),,Ki (nM),3600,PMID:16621549|DOI:10.1016/j.bmcl.2006.03.049,https://www.ncbi.nlm.nih.gov/pubmed/16621549|https://doi.org/10.1016/j.bmcl.2006.03.049,16621549,10.1016/j.bmcl.2006.03.049,
90,1963958,10487501,Comparative Toxicogenomics Database (CTD),2-Methylprop-1-enyl benzoate,C101261,2-methyl-1-propenylbenzoate,https://ctdbase.org/detail.go?type=chem&acc=C101261,590,BCHE,https://ctdbase.org/detail.go?type=gene&acc=590,,,590.0,BCHE,9606.0,Homo sapiens (human),BCHE protein results in increased hydrolysis of 2-methyl-1-propenylbenzoate,,,PMID:11590700,https://www.ncbi.nlm.nih.gov/pubmed/11590700,11590700,,
91,1963959,10491577,Therapeutic Target Database (TTD),"2-phenyl-2H-pyrazolo[3,4-c]quinolin-4-amine",D09HAM,"2-phenyl-2H-pyrazolo[3,4-c]quinolin-4-amine",https://idrblab.net/ttd/data/drug/details/D09HAM,T77365,Adenosine A2a receptor (ADORA2A),https://idrblab.net/ttd/data/target/details/T77365,P29274,Adenosine receptor A2a,135.0,ADORA2A,9606.0,Homo sapiens (human),Inhibitor,,,,,,,
92,1963960,10564794,Therapeutic Target Database (TTD),(4-Phenylethynyl-cyclohex-3-enyl)-dipropyl-amine,D09FTZ,(4-Phenylethynyl-cyclohex-3-enyl)-dipropyl-amine,https://idrblab.net/ttd/data/drug/details/D09FTZ,T24983,Dopamine D4 receptor (D4R),https://idrblab.net/ttd/data/target/details/T24983,P21917,D(4) dopamine receptor,1815.0,DRD4,9606.0,Homo sapiens (human),Inhibitor,,,,,,,
93,1963961,10566470,Therapeutic Target Database (TTD),5-Bromo-8-imidazol-1-ylmethyl-chromen-4-one,D0UI8Q,5-Bromo-8-imidazol-1-ylmethyl-chromen-4-one,https://idrblab.net/ttd/data/drug/details/D0UI8Q,T13260,Aromatase (CYP19A1),https://idrblab.net/ttd/data/target/details/T13260,P11511,Aromatase,1588.0,CYP19A1,9606.0,Homo sapiens (human),Inhibitor,,,,,,,
94,1963962,10574241,Therapeutic Target Database (TTD),3-[(S)-3-(Naphthalene-2-sulfonylamino)-2-oxo-pyrrolidin-1-ylmethyl]-benzamidine,D0MQ6K,RPR-118071,https://idrblab.net/ttd/data/drug/details/D0MQ6K,T24836,Vitamin K-dependent protein C (PROC),https://idrblab.net/ttd/data/target/details/T24836,P04070,Vitamin K-dependent protein C,5624.0,PROC,9606.0,Homo sapiens (human),Inhibitor,,,,,,,
95,1963802,11012291,BindingDB,"3-(prop-2-yn-1-ylamino)-2,3-dihydro-1H-inden-5-yl N-propylcarbamate",10764,"3-(prop-2-yn-1-ylamino)-2,3-dihydro-1H-inden-5-yl N-propylcarbamate",https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=10764,3619,Acetylcholinesterase,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=3619,P22303,Acetylcholinesterase,43.0,ACHE,9606.0,Homo sapiens (human),,IC50 (nM),2380,PMID:12431053|DOI:10.1021/jm020120c,https://www.ncbi.nlm.nih.gov/pubmed/12431053|https://doi.org/10.1021/jm020120c,12431053,10.1021/jm020120c,
96,1963803,11012291,BindingDB,"3-(prop-2-yn-1-ylamino)-2,3-dihydro-1H-inden-5-yl N-propylcarbamate",10764,"3-(prop-2-yn-1-ylamino)-2,3-dihydro-1H-inden-5-yl N-propylcarbamate",https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=10764,1130,Amine oxidase [flavin-containing] B,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=1130,P19643,Amine oxidase [flavin-containing] B,25750.0,Maob,10116.0,Rattus norvegicus (Norway rat),,IC50 (nM),25000,PMID:12431053|DOI:10.1021/jm020120c,https://www.ncbi.nlm.nih.gov/pubmed/12431053|https://doi.org/10.1021/jm020120c,12431053,10.1021/jm020120c,
97,1963804,11012291,BindingDB,"3-(prop-2-yn-1-ylamino)-2,3-dihydro-1H-inden-5-yl N-propylcarbamate",10764,"3-(prop-2-yn-1-ylamino)-2,3-dihydro-1H-inden-5-yl N-propylcarbamate",https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=10764,1129,Amine oxidase [flavin-containing] A,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=1129,P21396,Amine oxidase [flavin-containing] A ,,,10116.0,Rattus norvegicus (Norway rat),,IC50 (nM),69000,PMID:12431053|DOI:10.1021/jm020120c,https://www.ncbi.nlm.nih.gov/pubmed/12431053|https://doi.org/10.1021/jm020120c,12431053,10.1021/jm020120c,
98,1963805,11012293,BindingDB,"1-(prop-2-yn-1-ylamino)-2,3-dihydro-1H-inden-4-yl N-ethyl-N-methylcarbamate",10784,"1-(prop-2-yn-1-ylamino)-2,3-dihydro-1H-inden-4-yl N-ethyl-N-methylcarbamate",https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=10784,1129,Amine oxidase [flavin-containing] A,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=1129,P21396,Amine oxidase [flavin-containing] A ,,,10116.0,Rattus norvegicus (Norway rat),,IC50 (nM),830,PMID:12431053|DOI:10.1021/jm020120c,https://www.ncbi.nlm.nih.gov/pubmed/12431053|https://doi.org/10.1021/jm020120c,12431053,10.1021/jm020120c,
99,1963806,11012293,BindingDB,"1-(prop-2-yn-1-ylamino)-2,3-dihydro-1H-inden-4-yl N-ethyl-N-methylcarbamate",10784,"1-(prop-2-yn-1-ylamino)-2,3-dihydro-1H-inden-4-yl N-ethyl-N-methylcarbamate",https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=10784,254,Carboxylic ester hydrolase,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=254,,,,,,,,IC50 (nM),19,PMID:12431053|DOI:10.1021/jm020120c,https://www.ncbi.nlm.nih.gov/pubmed/12431053|https://doi.org/10.1021/jm020120c,12431053,10.1021/jm020120c,
100,1963807,11012293,BindingDB,"1-(prop-2-yn-1-ylamino)-2,3-dihydro-1H-inden-4-yl N-ethyl-N-methylcarbamate",10784,"1-(prop-2-yn-1-ylamino)-2,3-dihydro-1H-inden-4-yl N-ethyl-N-methylcarbamate",https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=10784,1130,Amine oxidase [flavin-containing] B,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=1130,P19643,Amine oxidase [flavin-containing] B,25750.0,Maob,10116.0,Rattus norvegicus (Norway rat),,IC50 (nM),150000,PMID:12431053|DOI:10.1021/jm020120c,https://www.ncbi.nlm.nih.gov/pubmed/12431053|https://doi.org/10.1021/jm020120c,12431053,10.1021/jm020120c,
101,1963808,11012293,BindingDB,"1-(prop-2-yn-1-ylamino)-2,3-dihydro-1H-inden-4-yl N-ethyl-N-methylcarbamate",10784,"1-(prop-2-yn-1-ylamino)-2,3-dihydro-1H-inden-4-yl N-ethyl-N-methylcarbamate",https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=10784,3619,Acetylcholinesterase,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=3619,P22303,Acetylcholinesterase,43.0,ACHE,9606.0,Homo sapiens (human),,IC50 (nM),2150,PMID:12431053|DOI:10.1021/jm020120c,https://www.ncbi.nlm.nih.gov/pubmed/12431053|https://doi.org/10.1021/jm020120c,12431053,10.1021/jm020120c,
102,1963809,11012721,BindingDB,"3-[ethyl(prop-2-yn-1-yl)amino]-2,3-dihydro-1H-inden-5-yl N,N-dimethylcarbamate",10776,"3-[ethyl(prop-2-yn-1-yl)amino]-2,3-dihydro-1H-inden-5-yl N,N-dimethylcarbamate",https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=10776,3619,Acetylcholinesterase,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=3619,P22303,Acetylcholinesterase,43.0,ACHE,9606.0,Homo sapiens (human),,IC50 (nM),17900,PMID:12431053|DOI:10.1021/jm020120c,https://www.ncbi.nlm.nih.gov/pubmed/12431053|https://doi.org/10.1021/jm020120c,12431053,10.1021/jm020120c,
103,1963810,11012721,BindingDB,"3-[ethyl(prop-2-yn-1-yl)amino]-2,3-dihydro-1H-inden-5-yl N,N-dimethylcarbamate",10776,"3-[ethyl(prop-2-yn-1-yl)amino]-2,3-dihydro-1H-inden-5-yl N,N-dimethylcarbamate",https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=10776,1130,Amine oxidase [flavin-containing] B,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=1130,P19643,Amine oxidase [flavin-containing] B,25750.0,Maob,10116.0,Rattus norvegicus (Norway rat),,IC50 (nM),>1000000,PMID:12431053|DOI:10.1021/jm020120c,https://www.ncbi.nlm.nih.gov/pubmed/12431053|https://doi.org/10.1021/jm020120c,12431053,10.1021/jm020120c,
104,1963811,11102680,BindingDB,1-[(3-carbamimidoylphenyl)methyl]-4-hydroxy-N-{[3-(trifluoromethyl)phenyl]methyl}-1H-indole-2-carboxamide,13883,1-[(3-carbamimidoylphenyl)methyl]-4-hydroxy-N-{[3-(trifluoromethyl)phenyl]methyl}-1H-indole-2-carboxamide,https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=13883,1341,Coagulation factor X,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=1341,P00742,Coagulation factor X,2159.0,F10,9606.0,Homo sapiens (human),,Ki (nM),476,PMID:12061878|DOI:10.1021/jm0111346,https://www.ncbi.nlm.nih.gov/pubmed/12061878|https://doi.org/10.1021/jm0111346,12061878,10.1021/jm0111346,
105,1963864,11291932,Therapeutic Target Database (TTD),"4-[3-(1,4-diazepan-1-ylcarbonyl)-4-fluorobenzyl]phthalazin-1(2H)-one",D09LSX,KU-0058948,https://idrblab.net/ttd/data/drug/details/D09LSX,T06273,Poly [ADP-ribose] polymerase 1 (PARP1),https://idrblab.net/ttd/data/target/details/T06273,P09874,Poly [ADP-ribose] polymerase 1,142.0,PARP1,9606.0,Homo sapiens (human),Inhibitor,,,,,,,
106,1963865,11294094,BindingDB,"(2S)-2-[(5-chloro-1,3-benzoxazol-2-yl)amino]-3-cyclohexyl-N-{2-[(4-fluorophenyl)amino]ethyl}propanamide",19619,"(2S)-2-[(5-chloro-1,3-benzoxazol-2-yl)amino]-3-cyclohexyl-N-{2-[(4-fluorophenyl)amino]ethyl}propanamide",https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=19619,5580,Cathepsin S,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=5580,P25774,Cathepsin S,1520.0,CTSS,9606.0,Homo sapiens (human),,Ki (nM),173,PMID:16446091|DOI:10.1016/j.bmcl.2005.12.095,https://www.ncbi.nlm.nih.gov/pubmed/16446091|https://doi.org/10.1016/j.bmcl.2005.12.095,16446091,10.1016/j.bmcl.2005.12.095,
107,1963866,11294094,BindingDB,"(2S)-2-[(5-chloro-1,3-benzoxazol-2-yl)amino]-3-cyclohexyl-N-{2-[(4-fluorophenyl)amino]ethyl}propanamide",19619,"(2S)-2-[(5-chloro-1,3-benzoxazol-2-yl)amino]-3-cyclohexyl-N-{2-[(4-fluorophenyl)amino]ethyl}propanamide",https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=19619,2012,Procathepsin L,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=2012,P07711,Procathepsin L,1514.0,CTSL,9606.0,Homo sapiens (human),,Ki (nM),11800,PMID:16446091|DOI:10.1016/j.bmcl.2005.12.095,https://www.ncbi.nlm.nih.gov/pubmed/16446091|https://doi.org/10.1016/j.bmcl.2005.12.095,16446091,10.1016/j.bmcl.2005.12.095,
108,1963867,11294094,BindingDB,"(2S)-2-[(5-chloro-1,3-benzoxazol-2-yl)amino]-3-cyclohexyl-N-{2-[(4-fluorophenyl)amino]ethyl}propanamide",19619,"(2S)-2-[(5-chloro-1,3-benzoxazol-2-yl)amino]-3-cyclohexyl-N-{2-[(4-fluorophenyl)amino]ethyl}propanamide",https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=19619,2049,Cathepsin K,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=2049,P43235,Cathepsin K,1513.0,CTSK,9606.0,Homo sapiens (human),,Ki (nM),>20000,PMID:16446091|DOI:10.1016/j.bmcl.2005.12.095,https://www.ncbi.nlm.nih.gov/pubmed/16446091|https://doi.org/10.1016/j.bmcl.2005.12.095,16446091,10.1016/j.bmcl.2005.12.095,
109,1963868,11294227,BindingDB,"(2S)-2-(1,3-benzoxazol-2-ylamino)-3-cyclohexyl-N-[(2S)-1-(5-fluoro-2,3-dihydro-1H-indol-1-yl)propan-2-yl]propanamide",19630,"(2S)-2-(1,3-benzoxazol-2-ylamino)-3-cyclohexyl-N-[(2S)-1-(5-fluoro-2,3-dihydro-1H-indol-1-yl)propan-2-yl]propanamide",https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=19630,5580,Cathepsin S,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=5580,P25774,Cathepsin S,1520.0,CTSS,9606.0,Homo sapiens (human),,Ki (nM),26,PMID:16446091|DOI:10.1016/j.bmcl.2005.12.095,https://www.ncbi.nlm.nih.gov/pubmed/16446091|https://doi.org/10.1016/j.bmcl.2005.12.095,16446091,10.1016/j.bmcl.2005.12.095,
110,1963869,11294227,BindingDB,"(2S)-2-(1,3-benzoxazol-2-ylamino)-3-cyclohexyl-N-[(2S)-1-(5-fluoro-2,3-dihydro-1H-indol-1-yl)propan-2-yl]propanamide",19630,"(2S)-2-(1,3-benzoxazol-2-ylamino)-3-cyclohexyl-N-[(2S)-1-(5-fluoro-2,3-dihydro-1H-indol-1-yl)propan-2-yl]propanamide",https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=19630,2049,Cathepsin K,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=2049,P43235,Cathepsin K,1513.0,CTSK,9606.0,Homo sapiens (human),,Ki (nM),>10000,PMID:16446091|DOI:10.1016/j.bmcl.2005.12.095,https://www.ncbi.nlm.nih.gov/pubmed/16446091|https://doi.org/10.1016/j.bmcl.2005.12.095,16446091,10.1016/j.bmcl.2005.12.095,
111,1963870,11294227,BindingDB,"(2S)-2-(1,3-benzoxazol-2-ylamino)-3-cyclohexyl-N-[(2S)-1-(5-fluoro-2,3-dihydro-1H-indol-1-yl)propan-2-yl]propanamide",19630,"(2S)-2-(1,3-benzoxazol-2-ylamino)-3-cyclohexyl-N-[(2S)-1-(5-fluoro-2,3-dihydro-1H-indol-1-yl)propan-2-yl]propanamide",https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=19630,2012,Procathepsin L,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=2012,P07711,Procathepsin L,1514.0,CTSL,9606.0,Homo sapiens (human),,Ki (nM),2830,PMID:16446091|DOI:10.1016/j.bmcl.2005.12.095,https://www.ncbi.nlm.nih.gov/pubmed/16446091|https://doi.org/10.1016/j.bmcl.2005.12.095,16446091,10.1016/j.bmcl.2005.12.095,
112,1962866,11314096,BindingDB,"(2R,4R,6S,7R)-7-(4-hydroxyphenyl)-4-(trifluoromethyl)-8-oxatricyclo[7.4.0.0;{2,6}]trideca-1(9),10,12-trien-12-ol",19983,"(2R,4R,6S,7R)-7-(4-hydroxyphenyl)-4-(trifluoromethyl)-8-oxatricyclo[7.4.0.0^{2,6}]trideca-1(9),10,12-trien-12-ol",https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=19983,369,Estrogen receptor,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=369,P03372,Estrogen receptor,2099.0,ESR1,9606.0,Homo sapiens (human),,Ki (nM),7.2,PMID:17614275|DOI:10.1016/j.bmcl.2007.06.052,https://www.ncbi.nlm.nih.gov/pubmed/17614275|https://doi.org/10.1016/j.bmcl.2007.06.052,17614275,10.1016/j.bmcl.2007.06.052,
113,1962867,11314096,BindingDB,"(2R,4R,6S,7R)-7-(4-hydroxyphenyl)-4-(trifluoromethyl)-8-oxatricyclo[7.4.0.0;{2,6}]trideca-1(9),10,12-trien-12-ol",19983,"(2R,4R,6S,7R)-7-(4-hydroxyphenyl)-4-(trifluoromethyl)-8-oxatricyclo[7.4.0.0^{2,6}]trideca-1(9),10,12-trien-12-ol",https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=19983,370,Estrogen receptor beta,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=370,Q92731,Estrogen receptor beta,2100.0,ESR2,9606.0,Homo sapiens (human),,Ki (nM),0.41,PMID:17614275|DOI:10.1016/j.bmcl.2007.06.052,https://www.ncbi.nlm.nih.gov/pubmed/17614275|https://doi.org/10.1016/j.bmcl.2007.06.052,17614275,10.1016/j.bmcl.2007.06.052,
114,1963902,11329788,BindingDB,"1-({3-[2-(2,4-Dichlorophenyl)ethoxy]-4-methoxyphenyl}carbonyl)-4-[(4-fluorophenyl)methyl]piperazine",13712,"1-({3-[2-(2,4-dichlorophenyl)ethoxy]-4-methoxyphenyl}carbonyl)-4-[(4-fluorophenyl)methyl]piperazine",https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=13712,1341,Coagulation factor X,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=1341,P00742,Coagulation factor X,2159.0,F10,9606.0,Homo sapiens (human),,Ki (nM),3925,PMID:15857135|DOI:10.1021/jm049187l,https://www.ncbi.nlm.nih.gov/pubmed/15857135|https://doi.org/10.1021/jm049187l,15857135,10.1021/jm049187l,
115,1963675,11380778,Comparative Toxicogenomics Database (CTD),"7,8-Diacetoxy-4-methylthiocoumarin",C540361,"7,8-diacetoxy-4-methylthiocoumarin",https://ctdbase.org/detail.go?type=chem&acc=C540361,598,BCL2L1,https://ctdbase.org/detail.go?type=gene&acc=598,,,598.0,BCL2L1,9606.0,Homo sapiens (human),"7,8-diacetoxy-4-methylthiocoumarin results in decreased expression of BCL2L1 protein",,,PMID:19061872,https://www.ncbi.nlm.nih.gov/pubmed/19061872,19061872,,
116,1963676,11380778,Comparative Toxicogenomics Database (CTD),"7,8-Diacetoxy-4-methylthiocoumarin",C540361,"7,8-diacetoxy-4-methylthiocoumarin",https://ctdbase.org/detail.go?type=chem&acc=C540361,836,CASP3,https://ctdbase.org/detail.go?type=gene&acc=836,,,836.0,CASP3,9606.0,Homo sapiens (human),"7,8-diacetoxy-4-methylthiocoumarin results in increased activity of CASP3 protein",,,PMID:19061872,https://www.ncbi.nlm.nih.gov/pubmed/19061872,19061872,,
117,1963677,11380778,Comparative Toxicogenomics Database (CTD),"7,8-Diacetoxy-4-methylthiocoumarin",C540361,"7,8-diacetoxy-4-methylthiocoumarin",https://ctdbase.org/detail.go?type=chem&acc=C540361,842,CASP9,https://ctdbase.org/detail.go?type=gene&acc=842,,,842.0,CASP9,9606.0,Homo sapiens (human),"7,8-diacetoxy-4-methylthiocoumarin results in increased activity of CASP9 protein",,,PMID:19061872,https://www.ncbi.nlm.nih.gov/pubmed/19061872,19061872,,
118,1963678,11380778,Comparative Toxicogenomics Database (CTD),"7,8-Diacetoxy-4-methylthiocoumarin",C540361,"7,8-diacetoxy-4-methylthiocoumarin",https://ctdbase.org/detail.go?type=chem&acc=C540361,54205,CYCS,https://ctdbase.org/detail.go?type=gene&acc=54205,,,54205.0,CYCS,9606.0,Homo sapiens (human),"7,8-diacetoxy-4-methylthiocoumarin affects the localization of CYCS protein",,,PMID:19061872,https://www.ncbi.nlm.nih.gov/pubmed/19061872,19061872,,
119,1963679,11380778,Comparative Toxicogenomics Database (CTD),"7,8-Diacetoxy-4-methylthiocoumarin",C540361,"7,8-diacetoxy-4-methylthiocoumarin",https://ctdbase.org/detail.go?type=chem&acc=C540361,5743,PTGS2,https://ctdbase.org/detail.go?type=gene&acc=5743,,,5743.0,PTGS2,9606.0,Homo sapiens (human),"7,8-diacetoxy-4-methylthiocoumarin results in decreased expression of PTGS2 protein",,,PMID:19061872,https://www.ncbi.nlm.nih.gov/pubmed/19061872,19061872,,
120,1963680,11380778,Comparative Toxicogenomics Database (CTD),"7,8-Diacetoxy-4-methylthiocoumarin",C540361,"7,8-diacetoxy-4-methylthiocoumarin",https://ctdbase.org/detail.go?type=chem&acc=C540361,5970,RELA,https://ctdbase.org/detail.go?type=gene&acc=5970,,,5970.0,RELA,9606.0,Homo sapiens (human),"7,8-diacetoxy-4-methylthiocoumarin inhibits the reaction [TNF protein affects the localization of RELA protein]",,,PMID:19061872,https://www.ncbi.nlm.nih.gov/pubmed/19061872,19061872,,
121,1963681,11380778,Comparative Toxicogenomics Database (CTD),"7,8-Diacetoxy-4-methylthiocoumarin",C540361,"7,8-diacetoxy-4-methylthiocoumarin",https://ctdbase.org/detail.go?type=chem&acc=C540361,7124,TNF,https://ctdbase.org/detail.go?type=gene&acc=7124,,,7124.0,TNF,9606.0,Homo sapiens (human),"7,8-diacetoxy-4-methylthiocoumarin inhibits the reaction [TNF protein affects the localization of RELA protein]",,,PMID:19061872,https://www.ncbi.nlm.nih.gov/pubmed/19061872,19061872,,
122,1962862,11384486,BindingDB,"Ether-based lactam, 19b",29073,"ether-based lactam, 19b",https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=29073,2137,Cannabinoid receptor 2,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=2137,P34972,Cannabinoid receptor 2 ,1269.0,CNR2,9606.0,Homo sapiens (human),,Ki (nM),>10000,PMID:19351113|DOI:10.1021/jm900255t,https://www.ncbi.nlm.nih.gov/pubmed/19351113|https://doi.org/10.1021/jm900255t,19351113,10.1021/jm900255t,
123,1962863,11386159,BindingDB,"2-Methyl-2-{2-methyl-4-[({3-[4-(trifluoromethoxy)phenyl]-1,2,4-thiadiazol-5-yl}methyl)sulfanyl]phenoxy}propanoic acid",28751,"2-methyl-2-{2-methyl-4-[({3-[4-(trifluoromethoxy)phenyl]-1,2,4-thiadiazol-5-yl}methyl)sulfanyl]phenoxy}propanoic acid",https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=28751,2209,Peroxisome proliferator-activated receptor gamma,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=2209,P37231,Peroxisome proliferator-activated receptor gamma,5468.0,PPARG,9606.0,Homo sapiens (human),,,,PMID:17608467|DOI:10.1021/jm070511x,https://www.ncbi.nlm.nih.gov/pubmed/17608467|https://doi.org/10.1021/jm070511x,17608467,10.1021/jm070511x,
124,1962864,11386159,BindingDB,"2-Methyl-2-{2-methyl-4-[({3-[4-(trifluoromethoxy)phenyl]-1,2,4-thiadiazol-5-yl}methyl)sulfanyl]phenoxy}propanoic acid",28751,"2-methyl-2-{2-methyl-4-[({3-[4-(trifluoromethoxy)phenyl]-1,2,4-thiadiazol-5-yl}methyl)sulfanyl]phenoxy}propanoic acid",https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=28751,9949,Peroxisome proliferator-activated receptor delta,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=9949,Q03181,Peroxisome proliferator-activated receptor delta,5467.0,PPARD,9606.0,Homo sapiens (human),,,,PMID:17608467|DOI:10.1021/jm070511x,https://www.ncbi.nlm.nih.gov/pubmed/17608467|https://doi.org/10.1021/jm070511x,17608467,10.1021/jm070511x,
125,1962865,11387011,BindingDB,"2-[(4-Tert-butylphenyl)methyl]-3-[2-(4-methanesulfonamidophenyl)propanamido]propyl 2,2-dimethylpropanoate",20289,"2-[(4-tert-butylphenyl)methyl]-3-[2-(4-methanesulfonamidophenyl)propanamido]propyl 2,2-dimethylpropanoate",https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=20289,2071,Transient receptor potential cation channel subfamily V member 1,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=2071,O35433,Transient receptor potential cation channel subfamily V member 1,83810.0,Trpv1,10116.0,Rattus norvegicus (Norway rat),,Ki (nM),55,PMID:18072720|DOI:10.1021/jm701049p,https://www.ncbi.nlm.nih.gov/pubmed/18072720|https://doi.org/10.1021/jm701049p,18072720,10.1021/jm701049p,
126,1962868,11395030,BindingDB,"4-{[(2R,5S)-5-{[(2S)-2-cyanopyrrolidin-1-yl]carbonyl}pyrrolidin-2-yl]methoxy}-3-(propan-2-yl)benzoic acid",11097,2-cyanopyrrolidine 21ad,https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=11097,1234,Dipeptidyl peptidase 4,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=1234,P27487,Dipeptidyl peptidase 4,1803.0,DPP4,9606.0,Homo sapiens (human),,Ki (nM),2.0,PMID:16759095|DOI:10.1021/jm051283e,https://www.ncbi.nlm.nih.gov/pubmed/16759095|https://doi.org/10.1021/jm051283e,16759095,10.1021/jm051283e,
127,1963896,11398207,BindingDB,"4-{[4-({3-[2-(2,4-Dichlorophenyl)ethoxy]-4-(hydroxymethyl)phenyl}carbonyl)piperazin-1-yl]methyl}-1-oxidopyridin-1-ium",13684,3-Oxybenzamide 70,https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=13684,1341,Coagulation factor X,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=1341,P00742,Coagulation factor X,2159.0,F10,9606.0,Homo sapiens (human),,Ki (nM),6200,PMID:15857135|DOI:10.1021/jm049187l,https://www.ncbi.nlm.nih.gov/pubmed/15857135|https://doi.org/10.1021/jm049187l,15857135,10.1021/jm049187l,
128,1963706,11401613,Therapeutic Target Database (TTD),4-Chlorobenzo[f]isoquinoline,D04ZIP,CBIQ,https://idrblab.net/ttd/data/drug/details/D04ZIP,T55654,cAMP-dependent chloride channel (CFTR),https://idrblab.net/ttd/data/target/details/T55654,P13569,Cystic fibrosis transmembrane conductance regulator,1080.0,CFTR,9606.0,Homo sapiens (human),Activator,,,,,,,
129,1963707,11404337,Drug Gene Interaction database (DGIdb),Obatoclax,,OBATOCLAX,https://www.dgidb.org/drugs/ncit:C60770,,BCL2,https://www.dgidb.org/genes/hgnc:990,,,596.0,BCL2,9606.0,Homo sapiens (human),Inhibitor,,,,,,,
130,1963708,11404337,DrugBank,Obatoclax,DB12191,Obatoclax,https://www.drugbank.ca/drugs/DB12191,BE0000246,Apoptosis regulator Bcl-2,https://www.drugbank.ca/bio_entities/BE0000246,P10415,Apoptosis regulator Bcl-2,596.0,BCL2,9606.0,Homo sapiens (human),,,,PMID:17505826|PMID:17227835,https://www.ncbi.nlm.nih.gov/pubmed/17505826|https://www.ncbi.nlm.nih.gov/pubmed/17227835,17505826|17227835,,
131,1963890,11411220,BindingDB,(2S)-2-{2-[4-(benzyloxy)-5-methoxy-2-(2-phenylacetyl)phenyl]-2-[(4-carbamimidoylphenyl)amino]acetamido}-2-phenylacetic acid,13555,(2S)-2-{2-[4-(benzyloxy)-5-methoxy-2-(2-phenylacetyl)phenyl]-2-[(4-carbamimidoylphenyl)amino]acetamido}-2-phenylacetic acid,https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=13555,1341,Coagulation factor X,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=1341,P00742,Coagulation factor X,2159.0,F10,9606.0,Homo sapiens (human),,Ki (nM),19000,PMID:15664864|DOI:10.1016/j.bmcl.2004.10.092,https://www.ncbi.nlm.nih.gov/pubmed/15664864|https://doi.org/10.1016/j.bmcl.2004.10.092,15664864,10.1016/j.bmcl.2004.10.092,
132,1963891,11411220,BindingDB,(2S)-2-{2-[4-(benzyloxy)-5-methoxy-2-(2-phenylacetyl)phenyl]-2-[(4-carbamimidoylphenyl)amino]acetamido}-2-phenylacetic acid,13555,(2S)-2-{2-[4-(benzyloxy)-5-methoxy-2-(2-phenylacetyl)phenyl]-2-[(4-carbamimidoylphenyl)amino]acetamido}-2-phenylacetic acid,https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=13555,334,Prothrombin,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=334,P00734,Prothrombin,2147.0,F2,9606.0,Homo sapiens (human),,Ki (nM),6400,PMID:15664864|DOI:10.1016/j.bmcl.2004.10.092,https://www.ncbi.nlm.nih.gov/pubmed/15664864|https://doi.org/10.1016/j.bmcl.2004.10.092,15664864,10.1016/j.bmcl.2004.10.092,
133,1963892,11411220,BindingDB,(2S)-2-{2-[4-(benzyloxy)-5-methoxy-2-(2-phenylacetyl)phenyl]-2-[(4-carbamimidoylphenyl)amino]acetamido}-2-phenylacetic acid,13555,(2S)-2-{2-[4-(benzyloxy)-5-methoxy-2-(2-phenylacetyl)phenyl]-2-[(4-carbamimidoylphenyl)amino]acetamido}-2-phenylacetic acid,https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=13555,1346,Coagulation factor VII,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=1346,P08709,Coagulation factor VII,2155.0,F7,9606.0,Homo sapiens (human),,Ki (nM),7,PMID:15664864|DOI:10.1016/j.bmcl.2004.10.092,https://www.ncbi.nlm.nih.gov/pubmed/15664864|https://doi.org/10.1016/j.bmcl.2004.10.092,15664864,10.1016/j.bmcl.2004.10.092,
134,1963893,11411220,BindingDB,(2S)-2-{2-[4-(benzyloxy)-5-methoxy-2-(2-phenylacetyl)phenyl]-2-[(4-carbamimidoylphenyl)amino]acetamido}-2-phenylacetic acid,13555,(2S)-2-{2-[4-(benzyloxy)-5-methoxy-2-(2-phenylacetyl)phenyl]-2-[(4-carbamimidoylphenyl)amino]acetamido}-2-phenylacetic acid,https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=13555,177,Serine protease 1,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=177,P00760,Cationic trypsin,615026.0,LOC615026,9913.0,Bos taurus (cattle),,Ki (nM),80,PMID:15664864|DOI:10.1016/j.bmcl.2004.10.092,https://www.ncbi.nlm.nih.gov/pubmed/15664864|https://doi.org/10.1016/j.bmcl.2004.10.092,15664864,10.1016/j.bmcl.2004.10.092,
135,1963899,11411220,BindingDB,(2S)-2-{2-[4-(benzyloxy)-5-methoxy-2-(2-phenylacetyl)phenyl]-2-[(4-carbamimidoylphenyl)amino]acetamido}-2-phenylacetic acid,13555,(2S)-2-{2-[4-(benzyloxy)-5-methoxy-2-(2-phenylacetyl)phenyl]-2-[(4-carbamimidoylphenyl)amino]acetamido}-2-phenylacetic acid,https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=13555,1346,Coagulation factor VII,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=1346,P08709,Coagulation factor VII,2155.0,F7,9606.0,Homo sapiens (human),,Ki (nM),7,PMID:16213138|DOI:10.1016/j.bmcl.2005.04.079,https://www.ncbi.nlm.nih.gov/pubmed/16213138|https://doi.org/10.1016/j.bmcl.2005.04.079,16213138,10.1016/j.bmcl.2005.04.079,
136,1963894,11418384,BindingDB,"3-Fluorophenylalanine derivative, 21b",34012,"3-fluorophenylalanine derivative, 21b",https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=34012,50002453,Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=50002453,Q13526,Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1,5300.0,PIN1,9606.0,Homo sapiens (human),,Ki (nM),6,PMID:19729306|DOI:10.1016/j.bmcl.2009.08.034,https://www.ncbi.nlm.nih.gov/pubmed/19729306|https://doi.org/10.1016/j.bmcl.2009.08.034,19729306,10.1016/j.bmcl.2009.08.034,
137,1963895,11419907,BindingDB,"N-{[4-(aminomethyl)cyclohexyl]methyl}-3-[2-(2,4-dichlorophenyl)ethoxy]-4-methoxybenzamide",13715,3-Oxybenzamide 101,https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=13715,1341,Coagulation factor X,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=1341,P00742,Coagulation factor X,2159.0,F10,9606.0,Homo sapiens (human),,Ki (nM),9345,PMID:15857135|DOI:10.1021/jm049187l,https://www.ncbi.nlm.nih.gov/pubmed/15857135|https://doi.org/10.1021/jm049187l,15857135,10.1021/jm049187l,
138,1963897,11431598,BindingDB,2-iodo-N-[3-[[(2R)-pyrrolidin-2-yl]methyl]-1H-indol-5-yl]benzenesulfonamide,34144,(R)-5a,https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=34144,2142,5-hydroxytryptamine receptor 6,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=2142,P50406,5-hydroxytryptamine receptor 6,3362.0,HTR6,9606.0,Homo sapiens (human),,Ki (nM),1,PMID:19758807|DOI:10.1016/j.bmc.2009.08.006,https://www.ncbi.nlm.nih.gov/pubmed/19758807|https://doi.org/10.1016/j.bmc.2009.08.006,19758807,10.1016/j.bmc.2009.08.006,
139,1963898,11431694,BindingDB,Tetrahydroisoquinoline (TIQ) deriv. 10b,13454,"N-[(3S)-3-(methylcarbamoyl)-2-{3-[4-(trifluoromethyl)phenyl]propanoyl}-1,2,3,4-tetrahydroisoquinolin-7-yl]sulfamic acid",https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=13454,1384,Tyrosine-protein phosphatase non-receptor type 1 [1-298],https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=1384,P18031,Tyrosine-protein phosphatase non-receptor type 1,5770.0,PTPN1,9606.0,Homo sapiens (human),,IC50 (nM),224800,PMID:16386905|DOI:10.1016/j.bmcl.2005.12.051,https://www.ncbi.nlm.nih.gov/pubmed/16386905|https://doi.org/10.1016/j.bmcl.2005.12.051,16386905,10.1016/j.bmcl.2005.12.051,
140,1963900,11436345,Therapeutic Target Database (TTD),"5-Methyl-5-(5-methylthiophen-3-yl)-4-oxo-4,5-dihydrofuran-2-carboxylic acid",D0J7LY,"5-methyl-5-(5-methylthiophen-3-yl)-4-oxo-4,5-dihydrofuran-2-carboxylic acid",https://idrblab.net/ttd/data/drug/details/D0J7LY,T00890,Hydroxycarboxylic acid receptor 3 (HCAR3),https://idrblab.net/ttd/data/target/details/T00890,P49019,Hydroxycarboxylic acid receptor 3,8843.0,HCAR3,9606.0,Homo sapiens (human),Agonist,,,,,,,
141,1963901,11441043,BindingDB,"3-Fluorophenylalanine derivative, 21a",34011,"3-fluorophenylalanine derivative, 21a",https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=34011,50002453,Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=50002453,Q13526,Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1,5300.0,PIN1,9606.0,Homo sapiens (human),,Ki (nM),8,PMID:19729306|DOI:10.1016/j.bmcl.2009.08.034,https://www.ncbi.nlm.nih.gov/pubmed/19729306|https://doi.org/10.1016/j.bmcl.2009.08.034,19729306,10.1016/j.bmcl.2009.08.034,
142,1962815,11524144,Comparative Toxicogenomics Database (CTD),Dorsomorphin,C516138,dorsomorphin,https://ctdbase.org/detail.go?type=chem&acc=C516138,326625,MMAB,https://ctdbase.org/detail.go?type=gene&acc=326625,,,326625.0,MMAB,9606.0,Homo sapiens (human),"[NOG protein co-treated with phenylmercuric acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MMAB mrna|[nog protein co-treated with p-chloromercuribenzoic acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MMAB mrna|[nog protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MMAB mRNA",,,PMID:27188386,https://www.ncbi.nlm.nih.gov/pubmed/27188386,27188386,,
143,1962869,11524144,Comparative Toxicogenomics Database (CTD),Dorsomorphin,C516138,dorsomorphin,https://ctdbase.org/detail.go?type=chem&acc=C516138,9848,MFAP3L,https://ctdbase.org/detail.go?type=gene&acc=9848,,,9848.0,MFAP3L,9606.0,Homo sapiens (human),"[NOG protein co-treated with panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MFAP3L mrna|[nog protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MFAP3L mrna|[nog protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MFAP3L mrna|[nog protein co-treated with p-chloromercuribenzoic acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MFAP3L mrna|[nog protein co-treated with phenylmercuric acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MFAP3L mrna|[nog protein co-treated with vorinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MFAP3L mrna|[nog protein co-treated with valproic acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MFAP3L mrna|[nog protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MFAP3L mRNA",,,PMID:27188386,https://www.ncbi.nlm.nih.gov/pubmed/27188386,27188386,,
144,1962870,11524144,Comparative Toxicogenomics Database (CTD),Dorsomorphin,C516138,dorsomorphin,https://ctdbase.org/detail.go?type=chem&acc=C516138,8076,MFAP5,https://ctdbase.org/detail.go?type=gene&acc=8076,,,8076.0,MFAP5,9606.0,Homo sapiens (human),"[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MFAP5 mrna|[nog protein co-treated with phenylmercuric acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MFAP5 mRNA",,,PMID:27188386,https://www.ncbi.nlm.nih.gov/pubmed/27188386,27188386,,
145,1962871,11524144,Comparative Toxicogenomics Database (CTD),Dorsomorphin,C516138,dorsomorphin,https://ctdbase.org/detail.go?type=chem&acc=C516138,9258,MFHAS1,https://ctdbase.org/detail.go?type=gene&acc=9258,,,9258.0,MFHAS1,9606.0,Homo sapiens (human),"[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MFHAS1 mrna|[nog protein co-treated with methylmercuric chloride co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MFHAS1 mRNA",,,PMID:27188386,https://www.ncbi.nlm.nih.gov/pubmed/27188386,27188386,,
146,1962872,11524144,Comparative Toxicogenomics Database (CTD),Dorsomorphin,C516138,dorsomorphin,https://ctdbase.org/detail.go?type=chem&acc=C516138,55669,MFN1,https://ctdbase.org/detail.go?type=gene&acc=55669,,,55669.0,MFN1,10116.0,Rattus norvegicus (Norway rat),Dorsomorphin results in decreased expression of MFN1 protein,,,PMID:27491814,https://www.ncbi.nlm.nih.gov/pubmed/27491814,27491814,,
147,1962873,11524144,Comparative Toxicogenomics Database (CTD),Dorsomorphin,C516138,dorsomorphin,https://ctdbase.org/detail.go?type=chem&acc=C516138,9927,MFN2,https://ctdbase.org/detail.go?type=gene&acc=9927,,,9927.0,MFN2,10090.0,Mus musculus (house mouse),Dorsomorphin inhibits the reaction [resveratrol results in increased expression of MFN2 mrna],,,PMID:17438283,https://www.ncbi.nlm.nih.gov/pubmed/17438283,17438283,,
148,1962874,11524144,Comparative Toxicogenomics Database (CTD),Dorsomorphin,C516138,dorsomorphin,https://ctdbase.org/detail.go?type=chem&acc=C516138,9927,MFN2,https://ctdbase.org/detail.go?type=gene&acc=9927,,,9927.0,MFN2,10116.0,Rattus norvegicus (Norway rat),Dorsomorphin inhibits the reaction [sappanone A inhibits the reaction [[oxygen deficiency co-treated with oxygen] results in decreased expression of MFN2 protein]],,,PMID:34358556,https://www.ncbi.nlm.nih.gov/pubmed/34358556,34358556,,
149,1962875,11524144,Comparative Toxicogenomics Database (CTD),Dorsomorphin,C516138,dorsomorphin,https://ctdbase.org/detail.go?type=chem&acc=C516138,4242,MFNG,https://ctdbase.org/detail.go?type=gene&acc=4242,,,4242.0,MFNG,9606.0,Homo sapiens (human),"[NOG protein co-treated with phenylmercuric acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MFNG mrna|[nog protein co-treated with valproic acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MFNG mrna|[nog protein co-treated with p-chloromercuribenzoic acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MFNG mrna|[nog protein co-treated with panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MFNG mrna|[nog protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MFNG mrna|[nog protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MFNG mrna|[nog protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MFNG mRNA",,,PMID:27188386,https://www.ncbi.nlm.nih.gov/pubmed/27188386,27188386,,
150,1962876,11524144,Comparative Toxicogenomics Database (CTD),Dorsomorphin,C516138,dorsomorphin,https://ctdbase.org/detail.go?type=chem&acc=C516138,64747,MFSD1,https://ctdbase.org/detail.go?type=gene&acc=64747,,,64747.0,MFSD1,9606.0,Homo sapiens (human),"[NOG protein co-treated with valproic acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MFSD1 mRNA",,,PMID:27188386,https://www.ncbi.nlm.nih.gov/pubmed/27188386,27188386,,
151,1962877,11524144,Comparative Toxicogenomics Database (CTD),Dorsomorphin,C516138,dorsomorphin,https://ctdbase.org/detail.go?type=chem&acc=C516138,113655,MFSD3,https://ctdbase.org/detail.go?type=gene&acc=113655,,,113655.0,MFSD3,9606.0,Homo sapiens (human),"[NOG protein co-treated with valproic acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MFSD3 mRNA",,,PMID:27188386,https://www.ncbi.nlm.nih.gov/pubmed/27188386,27188386,,
152,1962878,11524144,Comparative Toxicogenomics Database (CTD),Dorsomorphin,C516138,dorsomorphin,https://ctdbase.org/detail.go?type=chem&acc=C516138,4499,MT1M,https://ctdbase.org/detail.go?type=gene&acc=4499,,,4499.0,MT1M,9606.0,Homo sapiens (human),"[NOG protein co-treated with p-chloromercuribenzoic acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MT1M mrna|[nog protein co-treated with phenylmercuric acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MT1M mRNA",,,PMID:27188386,https://www.ncbi.nlm.nih.gov/pubmed/27188386,27188386,,
153,1962879,11524144,Comparative Toxicogenomics Database (CTD),Dorsomorphin,C516138,dorsomorphin,https://ctdbase.org/detail.go?type=chem&acc=C516138,55149,MTPAP,https://ctdbase.org/detail.go?type=gene&acc=55149,,,55149.0,MTPAP,9606.0,Homo sapiens (human),"[NOG protein co-treated with phenylmercuric acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MTPAP mRNA",,,PMID:27188386,https://www.ncbi.nlm.nih.gov/pubmed/27188386,27188386,,
154,1962880,11524144,Comparative Toxicogenomics Database (CTD),Dorsomorphin,C516138,dorsomorphin,https://ctdbase.org/detail.go?type=chem&acc=C516138,51250,MTRES1,https://ctdbase.org/detail.go?type=gene&acc=51250,,,51250.0,MTRES1,9606.0,Homo sapiens (human),"[NOG protein co-treated with valproic acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MTRES1 mRNA",,,PMID:27188386,https://www.ncbi.nlm.nih.gov/pubmed/27188386,27188386,,
155,1962881,11524144,Comparative Toxicogenomics Database (CTD),Dorsomorphin,C516138,dorsomorphin,https://ctdbase.org/detail.go?type=chem&acc=C516138,4501,MT1X,https://ctdbase.org/detail.go?type=gene&acc=4501,,,4501.0,MT1X,9606.0,Homo sapiens (human),"[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MT1X mrna|[nog protein co-treated with phenylmercuric acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MT1X mrna|[nog protein co-treated with valproic acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MT1X mrna|[nog protein co-treated with p-chloromercuribenzoic acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MT1X mRNA",,,PMID:27188386,https://www.ncbi.nlm.nih.gov/pubmed/27188386,27188386,,
156,1962918,11524144,Comparative Toxicogenomics Database (CTD),Dorsomorphin,C516138,dorsomorphin,https://ctdbase.org/detail.go?type=chem&acc=C516138,84709,MGARP,https://ctdbase.org/detail.go?type=gene&acc=84709,,,84709.0,MGARP,9606.0,Homo sapiens (human),"[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MGARP mrna|[nog protein co-treated with phenylmercuric acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MGARP mrna|[nog protein co-treated with valproic acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MGARP mrna|[nog protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MGARP mRNA",,,PMID:27188386,https://www.ncbi.nlm.nih.gov/pubmed/27188386,27188386,,
157,1962919,11524144,Comparative Toxicogenomics Database (CTD),Dorsomorphin,C516138,dorsomorphin,https://ctdbase.org/detail.go?type=chem&acc=C516138,11320,MGAT4A,https://ctdbase.org/detail.go?type=gene&acc=11320,,,11320.0,MGAT4A,9606.0,Homo sapiens (human),"[NOG protein co-treated with phenylmercuric acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MGAT4A mrna|[nog protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MGAT4A mRNA",,,PMID:27188386,https://www.ncbi.nlm.nih.gov/pubmed/27188386,27188386,,
158,1962920,11524144,Comparative Toxicogenomics Database (CTD),Dorsomorphin,C516138,dorsomorphin,https://ctdbase.org/detail.go?type=chem&acc=C516138,11282,MGAT4B,https://ctdbase.org/detail.go?type=gene&acc=11282,,,11282.0,MGAT4B,9606.0,Homo sapiens (human),"[NOG protein co-treated with phenylmercuric acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MGAT4B mrna|[nog protein co-treated with methylmercuric chloride co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MGAT4B mRNA",,,PMID:27188386,https://www.ncbi.nlm.nih.gov/pubmed/27188386,27188386,,
159,1962921,11524144,Comparative Toxicogenomics Database (CTD),Dorsomorphin,C516138,dorsomorphin,https://ctdbase.org/detail.go?type=chem&acc=C516138,4249,MGAT5,https://ctdbase.org/detail.go?type=gene&acc=4249,,,4249.0,MGAT5,9606.0,Homo sapiens (human),"[NOG protein co-treated with valproic acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MGAT5 mRNA",,,PMID:27188386,https://www.ncbi.nlm.nih.gov/pubmed/27188386,27188386,,
160,1962922,11524144,Comparative Toxicogenomics Database (CTD),Dorsomorphin,C516138,dorsomorphin,https://ctdbase.org/detail.go?type=chem&acc=C516138,146664,MGAT5B,https://ctdbase.org/detail.go?type=gene&acc=146664,,,146664.0,MGAT5B,9606.0,Homo sapiens (human),"[NOG protein co-treated with phenylmercuric acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MGAT5B mRNA",,,PMID:27188386,https://www.ncbi.nlm.nih.gov/pubmed/27188386,27188386,,
161,1962923,11524144,Comparative Toxicogenomics Database (CTD),Dorsomorphin,C516138,dorsomorphin,https://ctdbase.org/detail.go?type=chem&acc=C516138,216864,MGL2,https://ctdbase.org/detail.go?type=gene&acc=216864,,,216864.0,Mgl2,10090.0,Mus musculus (house mouse),Dorsomorphin inhibits the reaction [quercetin inhibits the reaction [lipopolysaccharides results in decreased expression of MGL2 mrna]]|dorsomorphin inhibits the reaction [AICA ribonucleotide results in increased expression of MGL2 mrna],,,PMID:24465016,https://www.ncbi.nlm.nih.gov/pubmed/24465016,24465016,,
162,1962924,11524144,Comparative Toxicogenomics Database (CTD),Dorsomorphin,C516138,dorsomorphin,https://ctdbase.org/detail.go?type=chem&acc=C516138,11343,MGLL,https://ctdbase.org/detail.go?type=gene&acc=11343,,,11343.0,MGLL,9606.0,Homo sapiens (human),"[NOG protein co-treated with phenylmercuric acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MGLL mRNA",,,PMID:27188386,https://www.ncbi.nlm.nih.gov/pubmed/27188386,27188386,,
163,1962925,11524144,Comparative Toxicogenomics Database (CTD),Dorsomorphin,C516138,dorsomorphin,https://ctdbase.org/detail.go?type=chem&acc=C516138,4257,MGST1,https://ctdbase.org/detail.go?type=gene&acc=4257,,,4257.0,MGST1,9606.0,Homo sapiens (human),"[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MGST1 mrna|[nog protein co-treated with vorinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MGST1 mrna|[nog protein co-treated with valproic acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MGST1 mRNA",,,PMID:27188386,https://www.ncbi.nlm.nih.gov/pubmed/27188386,27188386,,
164,1963779,11963952,BindingDB,"6-Arylpyrido[2,3-d]pyrimidine deriv. 80",3498,"1-[6-(2,6-dichlorophenyl)-2-{[3-(4-methylpiperazin-1-yl)propyl]amino}pyrido[2,3-d]pyrimidin-7-yl]benzeneguanidine",https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=3498,575,Platelet-derived growth factor receptor beta,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=575,P09619,Platelet-derived growth factor receptor beta,5159.0,PDGFRB,9606.0,Homo sapiens (human),,IC50 (nM),37000,PMID:11384237|DOI:10.1021/jm0004291,https://www.ncbi.nlm.nih.gov/pubmed/11384237|https://doi.org/10.1021/jm0004291,11384237,10.1021/jm0004291,
165,1963780,12005317,Drug Gene Interaction database (DGIdb),"3,4-dimethoxy-N-(4-methyl-2-piperidin-1-ylquinolin-6-yl)benzamide",,CHEMBL:CHEMBL527620,https://www.dgidb.org/drugs/chembl:CHEMBL527620,,MTOR,https://www.dgidb.org/genes/hgnc:3942,,,2475.0,MTOR,9606.0,Homo sapiens (human),,,,,,,,
166,1964249,12134997,Comparative Toxicogenomics Database (CTD),(E)-4-(2-(2-(N-((p-Methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide,C479799,(E)-4-((2-N-(4-methoxybenzenesulfonyl)amino)stilbazole)1-oxide,https://ctdbase.org/detail.go?type=chem&acc=C479799,5601,MAPK9,https://ctdbase.org/detail.go?type=gene&acc=5601,,,5601.0,MAPK9,9606.0,Homo sapiens (human),(E)-4-((2-N-(4-methoxybenzenesulfonyl)amino)stilbazole)1-oxide results in decreased expression of MAPK9 mRNA,,,PMID:15528975,https://www.ncbi.nlm.nih.gov/pubmed/15528975,15528975,,
167,1964250,12134997,Comparative Toxicogenomics Database (CTD),(E)-4-(2-(2-(N-((p-Methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide,C479799,(E)-4-((2-N-(4-methoxybenzenesulfonyl)amino)stilbazole)1-oxide,https://ctdbase.org/detail.go?type=chem&acc=C479799,5097,PCDH1,https://ctdbase.org/detail.go?type=gene&acc=5097,,,5097.0,PCDH1,9606.0,Homo sapiens (human),(E)-4-((2-N-(4-methoxybenzenesulfonyl)amino)stilbazole)1-oxide results in decreased expression of PCDH1 mRNA,,,PMID:15528975,https://www.ncbi.nlm.nih.gov/pubmed/15528975,15528975,,
168,1964251,12134997,Comparative Toxicogenomics Database (CTD),(E)-4-(2-(2-(N-((p-Methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide,C479799,(E)-4-((2-N-(4-methoxybenzenesulfonyl)amino)stilbazole)1-oxide,https://ctdbase.org/detail.go?type=chem&acc=C479799,10631,POSTN,https://ctdbase.org/detail.go?type=gene&acc=10631,,,10631.0,POSTN,9606.0,Homo sapiens (human),(E)-4-((2-N-(4-methoxybenzenesulfonyl)amino)stilbazole)1-oxide results in decreased expression of POSTN mRNA,,,PMID:15528975,https://www.ncbi.nlm.nih.gov/pubmed/15528975,15528975,,
169,1964252,12134997,Comparative Toxicogenomics Database (CTD),(E)-4-(2-(2-(N-((p-Methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide,C479799,(E)-4-((2-N-(4-methoxybenzenesulfonyl)amino)stilbazole)1-oxide,https://ctdbase.org/detail.go?type=chem&acc=C479799,5452,POU2F2,https://ctdbase.org/detail.go?type=gene&acc=5452,,,5452.0,POU2F2,9606.0,Homo sapiens (human),(E)-4-((2-N-(4-methoxybenzenesulfonyl)amino)stilbazole)1-oxide results in decreased expression of POU2F2 mRNA,,,PMID:15528975,https://www.ncbi.nlm.nih.gov/pubmed/15528975,15528975,,
170,1964253,12134997,Comparative Toxicogenomics Database (CTD),(E)-4-(2-(2-(N-((p-Methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide,C479799,(E)-4-((2-N-(4-methoxybenzenesulfonyl)amino)stilbazole)1-oxide,https://ctdbase.org/detail.go?type=chem&acc=C479799,5906,RAP1A,https://ctdbase.org/detail.go?type=gene&acc=5906,,,5906.0,RAP1A,9606.0,Homo sapiens (human),(E)-4-((2-N-(4-methoxybenzenesulfonyl)amino)stilbazole)1-oxide results in decreased expression of RAP1A mRNA,,,PMID:15528975,https://www.ncbi.nlm.nih.gov/pubmed/15528975,15528975,,
171,1964254,12134997,Comparative Toxicogenomics Database (CTD),(E)-4-(2-(2-(N-((p-Methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide,C479799,(E)-4-((2-N-(4-methoxybenzenesulfonyl)amino)stilbazole)1-oxide,https://ctdbase.org/detail.go?type=chem&acc=C479799,29984,RHOD,https://ctdbase.org/detail.go?type=gene&acc=29984,,,29984.0,RHOD,9606.0,Homo sapiens (human),(E)-4-((2-N-(4-methoxybenzenesulfonyl)amino)stilbazole)1-oxide results in decreased expression of RHOD mRNA,,,PMID:15528975,https://www.ncbi.nlm.nih.gov/pubmed/15528975,15528975,,
172,1964255,12134997,Comparative Toxicogenomics Database (CTD),(E)-4-(2-(2-(N-((p-Methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide,C479799,(E)-4-((2-N-(4-methoxybenzenesulfonyl)amino)stilbazole)1-oxide,https://ctdbase.org/detail.go?type=chem&acc=C479799,6708,SPTA1,https://ctdbase.org/detail.go?type=gene&acc=6708,,,6708.0,SPTA1,9606.0,Homo sapiens (human),(E)-4-((2-N-(4-methoxybenzenesulfonyl)amino)stilbazole)1-oxide results in decreased expression of SPTA1 mRNA,,,PMID:15528975,https://www.ncbi.nlm.nih.gov/pubmed/15528975,15528975,,
173,1964256,12134997,Comparative Toxicogenomics Database (CTD),(E)-4-(2-(2-(N-((p-Methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide,C479799,(E)-4-((2-N-(4-methoxybenzenesulfonyl)amino)stilbazole)1-oxide,https://ctdbase.org/detail.go?type=chem&acc=C479799,55578,SUPT20H,https://ctdbase.org/detail.go?type=gene&acc=55578,,,55578.0,SUPT20H,9606.0,Homo sapiens (human),(E)-4-((2-N-(4-methoxybenzenesulfonyl)amino)stilbazole)1-oxide results in decreased expression of SUPT20H mRNA,,,PMID:15528975,https://www.ncbi.nlm.nih.gov/pubmed/15528975,15528975,,
174,1964257,12134997,Comparative Toxicogenomics Database (CTD),(E)-4-(2-(2-(N-((p-Methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide,C479799,(E)-4-((2-N-(4-methoxybenzenesulfonyl)amino)stilbazole)1-oxide,https://ctdbase.org/detail.go?type=chem&acc=C479799,7015,TERT,https://ctdbase.org/detail.go?type=gene&acc=7015,,,7015.0,TERT,9606.0,Homo sapiens (human),(E)-4-((2-N-(4-methoxybenzenesulfonyl)amino)stilbazole)1-oxide results in decreased expression of TERT mRNA,,,PMID:15528975,https://www.ncbi.nlm.nih.gov/pubmed/15528975,15528975,,
175,1964258,12134997,Comparative Toxicogenomics Database (CTD),(E)-4-(2-(2-(N-((p-Methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide,C479799,(E)-4-((2-N-(4-methoxybenzenesulfonyl)amino)stilbazole)1-oxide,https://ctdbase.org/detail.go?type=chem&acc=C479799,7076,TIMP1,https://ctdbase.org/detail.go?type=gene&acc=7076,,,7076.0,TIMP1,9606.0,Homo sapiens (human),(E)-4-((2-N-(4-methoxybenzenesulfonyl)amino)stilbazole)1-oxide results in increased expression of TIMP1 mRNA,,,PMID:15528975,https://www.ncbi.nlm.nih.gov/pubmed/15528975,15528975,,
176,1963635,13643880,Toxin and Toxin Target Database (T3DB),Pentachloroarsorane,T3D1296,Arsenic pentachloride,http://www.t3db.ca/toxins/T3D1296,BE0001391,Tubulin alpha-4A chain,http://www.t3db.ca/biodb/bio_entities/BE0001391,P68366,Tubulin alpha-4A chain,7277.0,TUBA4A,9606.0,Homo sapiens (human),"Arsenic's carginogenicity is believed to be caused by the arsenical binding of tubulin, which results in aneuploidy, polyploidy and mitotic arrests. (A17)",,,PMID:18164070,https://www.ncbi.nlm.nih.gov/pubmed/18164070,18164070,,
177,1963636,13643880,Toxin and Toxin Target Database (T3DB),Pentachloroarsorane,T3D1296,Arsenic pentachloride,http://www.t3db.ca/toxins/T3D1296,BE0001359,Tubulin alpha-8 chain,http://www.t3db.ca/biodb/bio_entities/BE0001359,Q9NY65,Tubulin alpha-8 chain,51807.0,TUBA8,9606.0,Homo sapiens (human),"Arsenic's carginogenicity is believed to be caused by the arsenical binding of tubulin, which results in aneuploidy, polyploidy and mitotic arrests. (A17)",,,PMID:18164070,https://www.ncbi.nlm.nih.gov/pubmed/18164070,18164070,,
178,1963637,13643880,Toxin and Toxin Target Database (T3DB),Pentachloroarsorane,T3D1296,Arsenic pentachloride,http://www.t3db.ca/toxins/T3D1296,BE0000143,Tubulin beta chain,http://www.t3db.ca/biodb/bio_entities/BE0000143,P07437,Tubulin beta chain,203068.0,TUBB,9606.0,Homo sapiens (human),"Arsenic's carginogenicity is believed to be caused by the arsenical binding of tubulin, which results in aneuploidy, polyploidy and mitotic arrests. (A17)",,,PMID:18164070,https://www.ncbi.nlm.nih.gov/pubmed/18164070,18164070,,
179,1963638,13643880,Toxin and Toxin Target Database (T3DB),Pentachloroarsorane,T3D1296,Arsenic pentachloride,http://www.t3db.ca/toxins/T3D1296,BE0000026,Tubulin beta-1 chain,http://www.t3db.ca/biodb/bio_entities/BE0000026,Q9H4B7,Tubulin beta-1 chain,81027.0,TUBB1,9606.0,Homo sapiens (human),"Arsenic's carginogenicity is believed to be caused by the arsenical binding of tubulin, which results in aneuploidy, polyploidy and mitotic arrests. (A17)",,,PMID:18164070,https://www.ncbi.nlm.nih.gov/pubmed/18164070,18164070,,
180,1963639,13643880,Toxin and Toxin Target Database (T3DB),Pentachloroarsorane,T3D1296,Arsenic pentachloride,http://www.t3db.ca/toxins/T3D1296,BE0003400,Tubulin beta-2A chain,http://www.t3db.ca/biodb/bio_entities/BE0003400,Q13885,Tubulin beta-2A chain,7280.0,TUBB2A,9606.0,Homo sapiens (human),"Arsenic's carginogenicity is believed to be caused by the arsenical binding of tubulin, which results in aneuploidy, polyploidy and mitotic arrests. (A17)",,,PMID:18164070,https://www.ncbi.nlm.nih.gov/pubmed/18164070,18164070,,
181,1963640,13643880,Toxin and Toxin Target Database (T3DB),Pentachloroarsorane,T3D1296,Arsenic pentachloride,http://www.t3db.ca/toxins/T3D1296,BE0003401,Tubulin beta-2B chain,http://www.t3db.ca/biodb/bio_entities/BE0003401,Q9BVA1,Tubulin beta-2B chain,347733.0,TUBB2B,9606.0,Homo sapiens (human),"Arsenic's carginogenicity is believed to be caused by the arsenical binding of tubulin, which results in aneuploidy, polyploidy and mitotic arrests. (A17)",,,PMID:18164070,https://www.ncbi.nlm.nih.gov/pubmed/18164070,18164070,,
182,1963641,13643880,Toxin and Toxin Target Database (T3DB),Pentachloroarsorane,T3D1296,Arsenic pentachloride,http://www.t3db.ca/toxins/T3D1296,BE0001415,Tubulin beta-3 chain,http://www.t3db.ca/biodb/bio_entities/BE0001415,Q13509,Tubulin beta-3 chain,10381.0,TUBB3,9606.0,Homo sapiens (human),"Arsenic's carginogenicity is believed to be caused by the arsenical binding of tubulin, which results in aneuploidy, polyploidy and mitotic arrests. (A17)",,,PMID:18164070,https://www.ncbi.nlm.nih.gov/pubmed/18164070,18164070,,
183,1963642,13643880,Toxin and Toxin Target Database (T3DB),Pentachloroarsorane,T3D1296,Arsenic pentachloride,http://www.t3db.ca/toxins/T3D1296,BE0001408,Tubulin beta-4A chain,http://www.t3db.ca/biodb/bio_entities/BE0001408,P04350,Tubulin beta-4A chain,10382.0,TUBB4A,9606.0,Homo sapiens (human),"Arsenic's carginogenicity is believed to be caused by the arsenical binding of tubulin, which results in aneuploidy, polyploidy and mitotic arrests. (A17)",,,PMID:18164070,https://www.ncbi.nlm.nih.gov/pubmed/18164070,18164070,,
184,1963643,13643880,Toxin and Toxin Target Database (T3DB),Pentachloroarsorane,T3D1296,Arsenic pentachloride,http://www.t3db.ca/toxins/T3D1296,BE0001367,Tubulin beta-4B chain,http://www.t3db.ca/biodb/bio_entities/BE0001367,P68371,Tubulin beta-4B chain,10383.0,TUBB4B,9606.0,Homo sapiens (human),"Arsenic's carginogenicity is believed to be caused by the arsenical binding of tubulin, which results in aneuploidy, polyploidy and mitotic arrests. (A17)",,,PMID:18164070,https://www.ncbi.nlm.nih.gov/pubmed/18164070,18164070,,
185,1963832,13936691,Comparative Toxicogenomics Database (CTD),Eurycomanone,C506425,eurycomanone,https://ctdbase.org/detail.go?type=chem&acc=C506425,7157,TP53,https://ctdbase.org/detail.go?type=gene&acc=7157,,,7157.0,TP53,9606.0,Homo sapiens (human),Eurycomanone results in decreased expression of TP53 protein,,,PMID:21903368,https://www.ncbi.nlm.nih.gov/pubmed/21903368,21903368,,
186,1963833,13953710,IUPHAR/BPS Guide to PHARMACOLOGY,"Carbamic acid, (1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl)-, phenylmethyl ester (9CI)",7514,GW841819X,https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7514,1944,bromodomain containing 2,https://guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1944,P25440,Bromodomain-containing protein 2,6046.0,BRD2,9606.0,Homo sapiens (human),Inhibition,pIC50,7.52,PMID:21568322,https://www.ncbi.nlm.nih.gov/pubmed/21568322,21568322,,
187,1963834,13953710,IUPHAR/BPS Guide to PHARMACOLOGY,"Carbamic acid, (1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl)-, phenylmethyl ester (9CI)",7514,GW841819X,https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7514,1945,bromodomain containing 4,https://guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1945,O60885,Bromodomain-containing protein 4,23476.0,BRD4,9606.0,Homo sapiens (human),Inhibition,pIC50,7.81,PMID:21568322,https://www.ncbi.nlm.nih.gov/pubmed/21568322,21568322,,
188,1963835,14016348,IUPHAR/BPS Guide to PHARMACOLOGY,[125I]Abopx,452,[125I]ABOPX,https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=452,20,A2B receptor,https://guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=20,P29275,Adenosine receptor A2b,136.0,ADORA2B,9606.0,Homo sapiens (human),Antagonist,pKd,7.4,PMID:10496952,https://www.ncbi.nlm.nih.gov/pubmed/10496952,10496952,,
189,1963836,14126638,BindingDB,"Chalcone derivative, C",31276,"Chalcone derivative, C",https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=31276,3720,E3 ubiquitin-protein ligase Mdm2,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=3720,Q00987,E3 ubiquitin-protein ligase Mdm2,4193.0,MDM2,9606.0,Homo sapiens (human),,,,PMID:11148027|DOI:10.1021/bi000930v,https://www.ncbi.nlm.nih.gov/pubmed/11148027|https://doi.org/10.1021/bi000930v,11148027,10.1021/bi000930v,
190,1963837,14126638,BindingDB,"Chalcone derivative, C",31276,"Chalcone derivative, C",https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=31276,3720,E3 ubiquitin-protein ligase Mdm2,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=3720,Q00987,E3 ubiquitin-protein ligase Mdm2,4193.0,MDM2,9606.0,Homo sapiens (human),,IC50 (nM),250000,PMID:11148027|DOI:10.1021/bi000930v,https://www.ncbi.nlm.nih.gov/pubmed/11148027|https://doi.org/10.1021/bi000930v,11148027,10.1021/bi000930v,
191,1963838,14240392,Comparative Toxicogenomics Database (CTD),Curcumol,C022801,curcumol,https://ctdbase.org/detail.go?type=chem&acc=C022801,3791,KDR,https://ctdbase.org/detail.go?type=gene&acc=3791,,,3791.0,KDR,10090.0,Mus musculus (house mouse),Curcumol inhibits the reaction [carbon tetrachloride results in increased expression of KDR protein]|curcumol inhibits the reaction [VEGFA protein results in increased expression of KDR protein]|curcumol inhibits the reaction [VEGFA protein results in increased expression of KDR mrna]|atg5 protein inhibits the reaction [curcumol inhibits the reaction [carbon tetrachloride results in increased expression of KDR protein]]|[klf5 protein co-treated with curcumol] inhibits the reaction [VEGFA protein results in increased expression of KDR protein]|klf5 protein inhibits the reaction [curcumol inhibits the reaction [carbon tetrachloride results in increased expression of KDR protein]],,,PMID:33549628,https://www.ncbi.nlm.nih.gov/pubmed/33549628,33549628,,
192,1963839,14240392,Comparative Toxicogenomics Database (CTD),Curcumol,C022801,curcumol,https://ctdbase.org/detail.go?type=chem&acc=C022801,688,KLF5,https://ctdbase.org/detail.go?type=gene&acc=688,,,688.0,KLF5,10090.0,Mus musculus (house mouse),[KLF5 protein co-treated with curcumol] inhibits the reaction [VEGFA protein results in increased expression of PDGFBB protein]|atg5 protein inhibits the reaction [curcumol inhibits the reaction [VEGFA protein results in increased expression of KLF5 mrna]]|sqstm1 protein affects the reaction [curcumol inhibits the reaction [VEGFA protein results in increased expression of KLF5 mrna]]|curcumol inhibits the reaction [VEGFA protein results in increased expression of KLF5 protein]|curcumol promotes the reaction [SQSTM1 protein binds to KLF5 protein]|[klf5 protein co-treated with curcumol] inhibits the reaction [VEGFA protein results in increased expression of HIF1A protein]|[klf5 protein co-treated with curcumol] inhibits the reaction [VEGFA protein results in increased expression of ANGPT2 protein]|klf5 protein inhibits the reaction [curcumol inhibits the reaction [carbon tetrachloride results in increased expression of CD34 protein]]|klf5 protein inhibits the reaction [curcumol inhibits the reaction [carbon tetrachloride results in increased expression of VWF protein]]|klf5 protein inhibits the reaction [curcumol inhibits the reaction [carbon tetrachloride results in increased activity of GPT protein]]|curcumol inhibits the reaction [VEGFA protein results in increased expression of KLF5 mrna]|atg5 protein inhibits the reaction [curcumol inhibits the reaction [VEGFA protein results in increased expression of KLF5 protein]]|klf5 protein inhibits the reaction [curcumol inhibits the reaction [carbon tetrachloride results in increased expression of PECAM1 protein]]|[klf5 protein co-treated with curcumol] inhibits the reaction [VEGFA protein results in increased expression of KDR protein]|klf5 protein inhibits the reaction [curcumol inhibits the reaction [carbon tetrachloride results in increased expression of KDR protein]]|klf5 protein inhibits the reaction [curcumol inhibits the reaction [carbon tetrachloride results in increased expression of VEGFA protein]],,,PMID:33549628,https://www.ncbi.nlm.nih.gov/pubmed/33549628,33549628,,
193,1963840,14240392,Comparative Toxicogenomics Database (CTD),Curcumol,C022801,curcumol,https://ctdbase.org/detail.go?type=chem&acc=C022801,81631,MAP1LC3B,https://ctdbase.org/detail.go?type=gene&acc=81631,,,81631.0,MAP1LC3B,10116.0,Rattus norvegicus (Norway rat),Curcumol inhibits the reaction [VEGFA protein results in increased expression of MAP1LC3B mrna],,,PMID:33549628,https://www.ncbi.nlm.nih.gov/pubmed/33549628,33549628,,
194,1963841,14240392,Comparative Toxicogenomics Database (CTD),Curcumol,C022801,curcumol,https://ctdbase.org/detail.go?type=chem&acc=C022801,2475,MTOR,https://ctdbase.org/detail.go?type=gene&acc=2475,,,2475.0,MTOR,10116.0,Rattus norvegicus (Norway rat),Curcumol inhibits the reaction [VEGFA protein results in decreased phosphorylation of MTOR protein],,,PMID:33549628,https://www.ncbi.nlm.nih.gov/pubmed/33549628,33549628,,
195,1963861,14240392,Comparative Toxicogenomics Database (CTD),Curcumol,C022801,curcumol,https://ctdbase.org/detail.go?type=chem&acc=C022801,2875,GPT,https://ctdbase.org/detail.go?type=gene&acc=2875,,,2875.0,GPT,10090.0,Mus musculus (house mouse),Curcumol inhibits the reaction [carbon tetrachloride results in increased activity of GPT protein]|klf5 protein inhibits the reaction [curcumol inhibits the reaction [carbon tetrachloride results in increased activity of GPT protein]]|atg5 protein inhibits the reaction [curcumol inhibits the reaction [carbon tetrachloride results in increased activity of GPT protein]],,,PMID:33549628,https://www.ncbi.nlm.nih.gov/pubmed/33549628,33549628,,
196,1963862,14240392,Comparative Toxicogenomics Database (CTD),Curcumol,C022801,curcumol,https://ctdbase.org/detail.go?type=chem&acc=C022801,2875,GPT,https://ctdbase.org/detail.go?type=gene&acc=2875,,,2875.0,GPT,10090.0,Mus musculus (house mouse),Curcumol inhibits the reaction [carbon tetrachloride results in increased expression of GPT protein],,,PMID:32344006,https://www.ncbi.nlm.nih.gov/pubmed/32344006,32344006,,
197,1963863,14240392,Comparative Toxicogenomics Database (CTD),Curcumol,C022801,curcumol,https://ctdbase.org/detail.go?type=chem&acc=C022801,3091,HIF1A,https://ctdbase.org/detail.go?type=gene&acc=3091,,,3091.0,HIF1A,10116.0,Rattus norvegicus (Norway rat),[ATG5 protein co-treated with curcumol] inhibits the reaction [VEGFA protein results in increased expression of HIF1A protein]|[klf5 protein co-treated with curcumol] inhibits the reaction [VEGFA protein results in increased expression of HIF1A protein]|curcumol inhibits the reaction [VEGFA protein results in increased expression of HIF1A protein]|curcumol inhibits the reaction [VEGFA protein results in increased expression of HIF1A mrna],,,PMID:33549628,https://www.ncbi.nlm.nih.gov/pubmed/33549628,33549628,,
198,1963995,14314897,Drug Gene Interaction database (DGIdb),"alpha,beta-Dehydrocurvularin",,CHEMBL:CHEMBL482050,https://www.dgidb.org/drugs/chembl:CHEMBL482050,,NFE2L2,https://www.dgidb.org/genes/hgnc:7782,,,4780.0,NFE2L2,9606.0,Homo sapiens (human),,,,,,,,
199,1963996,14314897,Drug Gene Interaction database (DGIdb),"alpha,beta-Dehydrocurvularin",,CHEMBL:CHEMBL482050,https://www.dgidb.org/drugs/chembl:CHEMBL482050,,MITF,https://www.dgidb.org/genes/hgnc:7105,,,4286.0,MITF,9606.0,Homo sapiens (human),,,,,,,,
200,1963997,14314897,Drug Gene Interaction database (DGIdb),"alpha,beta-Dehydrocurvularin",,CHEMBL:CHEMBL482050,https://www.dgidb.org/drugs/chembl:CHEMBL482050,,GLP1R,https://www.dgidb.org/genes/hgnc:4324,,,2740.0,GLP1R,9606.0,Homo sapiens (human),,,,,,,,
201,1963998,14392072,BindingDB,2-(4-Methoxybenzyl)Malonic Acid,86129,"LDHA Inhibitor, 25",https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=86129,5049,L-lactate dehydrogenase A chain,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=5049,P04642,L-lactate dehydrogenase A chain,24533.0,Ldha,10116.0,Rattus norvegicus (Norway rat),,,,PMID:22417091|DOI:10.1021/jm201734r,https://www.ncbi.nlm.nih.gov/pubmed/22417091|https://doi.org/10.1021/jm201734r,22417091,10.1021/jm201734r,
202,1963999,14392072,BindingDB,2-(4-Methoxybenzyl)Malonic Acid,86129,"LDHA Inhibitor, 25",https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=86129,5049,L-lactate dehydrogenase A chain,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=5049,P04642,L-lactate dehydrogenase A chain,24533.0,Ldha,10116.0,Rattus norvegicus (Norway rat),,,,PMID:22417091|DOI:10.1021/jm201734r,https://www.ncbi.nlm.nih.gov/pubmed/22417091|https://doi.org/10.1021/jm201734r,22417091,10.1021/jm201734r,
203,1964000,14392072,BindingDB,2-(4-Methoxybenzyl)Malonic Acid,86129,"LDHA Inhibitor, 25",https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=86129,5049,L-lactate dehydrogenase A chain,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=5049,P04642,L-lactate dehydrogenase A chain,24533.0,Ldha,10116.0,Rattus norvegicus (Norway rat),,IC50 (nM),>5.00e+5,PMID:22417091|DOI:10.1021/jm201734r,https://www.ncbi.nlm.nih.gov/pubmed/22417091|https://doi.org/10.1021/jm201734r,22417091,10.1021/jm201734r,
204,1963777,16045336,DrugBank,3-chloro-5-[2-chloro-5-(1H-indazol-3-ylmethoxy)phenoxy]benzonitrile,DB08154,3-chloro-5-[2-chloro-5-(1H-indazol-3-ylmethoxy)phenoxy]benzonitrile,https://www.drugbank.ca/drugs/DB08154,BE0001594,Gag-Pol polyprotein,https://www.drugbank.ca/bio_entities/BE0001594,P04585,Gag-Pol polyprotein,155348.0,gag-pol,11706.0,HIV-1 M:B_HXB2R,,,,PMID:10592235,https://www.ncbi.nlm.nih.gov/pubmed/10592235,10592235,,
205,1963772,16045418,DrugBank,"3-(5-((6-Amino-1H-pyrazolo[3,4-b]pyridin-3-yl)methoxy)-2-chlorophenoxy)-5-chlorobenzonitrile",DB08460,MK-4965,https://www.drugbank.ca/drugs/DB08460,BE0001594,Gag-Pol polyprotein,https://www.drugbank.ca/bio_entities/BE0001594,P04585,Gag-Pol polyprotein,155348.0,gag-pol,11706.0,HIV-1 M:B_HXB2R,,,,PMID:10592235,https://www.ncbi.nlm.nih.gov/pubmed/10592235,10592235,,
206,1963771,16051968,Drug Gene Interaction database (DGIdb),Haloperidol Lactate,,HALOPERIDOL LACTATE,https://www.dgidb.org/drugs/rxcui:217483,,DRD3,https://www.dgidb.org/genes/hgnc:3024,,,1814.0,DRD3,9606.0,Homo sapiens (human),Inverse agonist,,,,,,,
207,1963773,16058682,DrugBank,"(1S,4S,5S)-1,4,5-Trihydroxy-3-[3-(phenylthio)phenyl]cyclohex-2-ene-1-carboxylic acid",DB08485,"(1S,4S,5S)-1,4,5-TRIHYDROXY-3-[3-(PHENYLTHIO)PHENYL]CYCLOHEX-2-ENE-1-CARBOXYLIC ACID",https://www.drugbank.ca/drugs/DB08485,BE0001769,3-dehydroquinate dehydratase,https://www.drugbank.ca/bio_entities/BE0001769,P15474,3-dehydroquinate dehydratase,,,100226.0,Streptomyces coelicolor A3(2),,,,PMID:10592235,https://www.ncbi.nlm.nih.gov/pubmed/10592235,10592235,,
208,1963774,16063245,ChEMBL,Radotinib,CHEMBL4297524,RADOTINIB,https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4297524/,CHEMBL2096618,Bcr/Abl fusion protein,https://www.ebi.ac.uk/chembl/target_report_card/CHEMBL2096618/,P00519,Tyrosine-protein kinase ABL1,25.0,ABL1,9606.0,Homo sapiens (human),Bcr/abl fusion protein inhibitor,,,PMID:29051802|PMID:24705186|PMID:25676420,https://www.ncbi.nlm.nih.gov/pubmed/29051802|https://www.ncbi.nlm.nih.gov/pubmed/24705186|https://www.ncbi.nlm.nih.gov/pubmed/25676420,29051802|24705186|25676420,,
209,1963775,16063245,ChEMBL,Radotinib,CHEMBL4297524,RADOTINIB,https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4297524/,CHEMBL2096618,Bcr/Abl fusion protein,https://www.ebi.ac.uk/chembl/target_report_card/CHEMBL2096618/,P11274,Breakpoint cluster region protein,613.0,BCR,9606.0,Homo sapiens (human),Bcr/abl fusion protein inhibitor,,,PMID:29051802|PMID:24705186|PMID:25676420,https://www.ncbi.nlm.nih.gov/pubmed/29051802|https://www.ncbi.nlm.nih.gov/pubmed/24705186|https://www.ncbi.nlm.nih.gov/pubmed/25676420,29051802|24705186|25676420,,
210,1963776,16072188,Comparative Toxicogenomics Database (CTD),Azamulin,C489644,azamulin,https://ctdbase.org/detail.go?type=chem&acc=C489644,1576,CYP3A4,https://ctdbase.org/detail.go?type=gene&acc=1576,,,1576.0,CYP3A4,9606.0,Homo sapiens (human),Azamulin results in decreased activity of CYP3A4 protein,,,PMID:15860655,https://www.ncbi.nlm.nih.gov/pubmed/15860655,15860655,,
211,1963778,16086836,DrugBank,"3-({3-[(1S,4aS,6S,7S,9S,9aR)-1,6-dimethyl-2-oxodecahydro-6,9-epoxy-4a,7-methanobenzo[7]annulen-1-yl]propanoyl}amino)-2,4-dihydroxybenzoic acid",DB08366,"3-({3-[(1S,4aS,6S,7S,9S,9aR)-1,6-dimethyl-2-oxodecahydro-6,9-epoxy-4a,7-methanobenzo[7]annulen-1-yl]propanoyl}amino)-2,4-dihydroxybenzoic acid",https://www.drugbank.ca/drugs/DB08366,BE0000800,3-oxoacyl-[acyl-carrier-protein] synthase 2,https://www.drugbank.ca/bio_entities/BE0000800,P0AAI5,3-oxoacyl-[acyl-carrier-protein] synthase 2,75203681.0,,83333.0,Escherichia coli K-12,,,,PMID:10592235,https://www.ncbi.nlm.nih.gov/pubmed/10592235,10592235,,
212,1964080,16086911,BindingDB,"3,3-Bis(4-hydroxyphenyl)benzo[g]isobenzofuran-1-one",18756,"1,2-naphthalein derivative, 2",https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=18756,1936,Thymidylate synthase,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=1936,P04818,Thymidylate synthase,7298.0,TYMS,9606.0,Homo sapiens (human),,Ki (nM),400,PMID:17004711|DOI:10.1021/jm051187d,https://www.ncbi.nlm.nih.gov/pubmed/17004711|https://doi.org/10.1021/jm051187d,17004711,10.1021/jm051187d,
213,1964081,16086911,BindingDB,"3,3-Bis(4-hydroxyphenyl)benzo[g]isobenzofuran-1-one",18756,"1,2-naphthalein derivative, 2",https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=18756,1875,Dihydrofolate reductase,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=1875,P00374,Dihydrofolate reductase,1719.0,DHFR,9606.0,Homo sapiens (human),,Ki (nM),35000,PMID:17004711|DOI:10.1021/jm051187d,https://www.ncbi.nlm.nih.gov/pubmed/17004711|https://doi.org/10.1021/jm051187d,17004711,10.1021/jm051187d,
214,1964082,16086912,BindingDB,"1,1-Bis(4-hydroxy-3-iodo-phenyl)benzo[e]isobenzofuran-3-one",18757,"1,2-naphthalein derivative, 3",https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=18757,1875,Dihydrofolate reductase,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=1875,P00374,Dihydrofolate reductase,1719.0,DHFR,9606.0,Homo sapiens (human),,Ki (nM),3900,PMID:17004711|DOI:10.1021/jm051187d,https://www.ncbi.nlm.nih.gov/pubmed/17004711|https://doi.org/10.1021/jm051187d,17004711,10.1021/jm051187d,
215,1964111,16086916,BindingDB,"3,3-Bis(3-chloro-4-hydroxy-phenyl)benzo[g]isobenzofuran-1-one",18760,"1,2-naphthalein derivative, 7",https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=18760,1933,Thymidylate synthase,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=1933,P0A884,Thymidylate synthase,83579666.0,,83333.0,Escherichia coli K-12,,Ki (nM),1200,PMID:17004711|DOI:10.1021/jm051187d,https://www.ncbi.nlm.nih.gov/pubmed/17004711|https://doi.org/10.1021/jm051187d,17004711,10.1021/jm051187d,
216,1964112,16086916,BindingDB,"3,3-Bis(3-chloro-4-hydroxy-phenyl)benzo[g]isobenzofuran-1-one",18760,"1,2-naphthalein derivative, 7",https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=18760,1932,Thymidylate synthase,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=1932,P0CS13,Thymidylate synthase,4938566.0,CNBJ2230,283643.0,Cryptococcus neoformans var. neoformans B-3501A,,Ki (nM),8100,PMID:17004711|DOI:10.1021/jm051187d,https://www.ncbi.nlm.nih.gov/pubmed/17004711|https://doi.org/10.1021/jm051187d,17004711,10.1021/jm051187d,
217,1964113,16086916,BindingDB,"3,3-Bis(3-chloro-4-hydroxy-phenyl)benzo[g]isobenzofuran-1-one",18760,"1,2-naphthalein derivative, 7",https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=18760,1934,Thymidylate synthase,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=1934,P00469,Thymidylate synthase,,,1582.0,Lacticaseibacillus casei,,Ki (nM),3900,PMID:17004711|DOI:10.1021/jm051187d,https://www.ncbi.nlm.nih.gov/pubmed/17004711|https://doi.org/10.1021/jm051187d,17004711,10.1021/jm051187d,
218,1964114,16086917,BindingDB,"3,3-Bis(3-fluoro-4-hydroxy-phenyl)benzo[g]isobenzofuran-1-one",18761,"1,2-naphthalein derivative, 8",https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=18761,1934,Thymidylate synthase,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=1934,P00469,Thymidylate synthase,,,1582.0,Lacticaseibacillus casei,,Ki (nM),1400,PMID:17004711|DOI:10.1021/jm051187d,https://www.ncbi.nlm.nih.gov/pubmed/17004711|https://doi.org/10.1021/jm051187d,17004711,10.1021/jm051187d,
219,1982412,16110428,BindingDB,"2-[(1S)-5-{3-[4-(1H-1,2,4-triazol-1-yl)phenoxy]propoxy}-2,3-dihydro-1H-inden-1-yl]acetic acid",21774,"2-[(1S)-5-{3-[4-(1H-1,2,4-triazol-1-yl)phenoxy]propoxy}-2,3-dihydro-1H-inden-1-yl]acetic acid",https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=21774,2209,Peroxisome proliferator-activated receptor gamma,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=2209,P37231,Peroxisome proliferator-activated receptor gamma,5468.0,PPARG,9606.0,Homo sapiens (human),,,,PMID:17274610|DOI:10.1021/jm061299k,https://www.ncbi.nlm.nih.gov/pubmed/17274610|https://doi.org/10.1021/jm061299k,17274610,10.1021/jm061299k,
220,1963682,21023902,Therapeutic Target Database (TTD),"2-bromo-4,5-dimethoxy-N-[3-[(3R)-1-methylpyrrolidin-3-yl]oxy-4-(trifluoromethyl)phenyl]benzenesulfonamide",D07JDU,SB-706375,https://idrblab.net/ttd/data/drug/details/D07JDU,T49072,Urotensin II receptor (UTS2R),https://idrblab.net/ttd/data/target/details/T49072,Q9UKP6,Urotensin-2 receptor,2837.0,UTS2R,9606.0,Homo sapiens (human),Inhibitor,,,,,,,
221,1963683,21137645,BindingDB,"benzyl N-{4-methyl-5-[(2,4,6-trimethylphenyl)carbamoyl]-1,3-thiazol-2-yl}carbamate",13230,"2-[[(Benzyloxy)carbonyl]-amino]-4-methyl-N-(2,4,6-trimethylphenyl)-1,3-thiazole-5-carboxamide",https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=13230,50000539,Proto-oncogene tyrosine-protein kinase LCK,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=50000539,P06240,Proto-oncogene tyrosine-protein kinase LCK ,16818.0,Lck,10090.0,Mus musculus (house mouse),,IC50 (nM),33320,PMID:17154512|DOI:10.1021/jm060727j,https://www.ncbi.nlm.nih.gov/pubmed/17154512|https://doi.org/10.1021/jm060727j,17154512,10.1021/jm060727j,
222,1963684,21137651,BindingDB,"methyl N-{4-methyl-5-[(2,4,6-trimethylphenyl)carbamoyl]-1,3-thiazol-2-yl}carbamate",13222,"2-[[(Methoxy)carbonyl]-amino]-4-methyl-N-(2,4,6-trimethylphenyl)-1,3-thiazole-5-carboxamide",https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=13222,50000539,Proto-oncogene tyrosine-protein kinase LCK,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=50000539,P06240,Proto-oncogene tyrosine-protein kinase LCK ,16818.0,Lck,10090.0,Mus musculus (house mouse),,IC50 (nM),720,PMID:17154512|DOI:10.1021/jm060727j,https://www.ncbi.nlm.nih.gov/pubmed/17154512|https://doi.org/10.1021/jm060727j,17154512,10.1021/jm060727j,
223,1964481,21177863,BindingDB,"(1E,4E)-1,5-bis[4-(diethylamino)phenyl]penta-1,4-dien-3-one",111812,"(1E,4E)&#8208;1,5&#8208;bis[4&#8208;(diethylamino)phenyl]penta&#8208;1,4&#8208; dien&#8208;3&#8208;one (11)",https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=111812,2262,Prostaglandin G/H synthase 2,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=2262,P35354,Prostaglandin G/H synthase 2,5743.0,PTGS2,9606.0,Homo sapiens (human),,IC50 (nM),9.486e+4,PMID:24406103|DOI:10.1111/cbdd.12280,https://www.ncbi.nlm.nih.gov/pubmed/24406103|https://doi.org/10.1111/cbdd.12280,24406103,10.1111/cbdd.12280,
224,2001093,21944094,Comparative Toxicogenomics Database (CTD),Rapamycin (Sirolimus),D020123,Sirolimus,https://ctdbase.org/detail.go?type=chem&acc=D020123,7124,TNF,https://ctdbase.org/detail.go?type=gene&acc=7124,,,7124.0,TNF,10090.0,Mus musculus (house mouse),Sirolimus inhibits the reaction [TNF protein results in increased phosphorylation of EIF4EBP1 protein],,,PMID:14502240,https://www.ncbi.nlm.nih.gov/pubmed/14502240,14502240,,
225,2001094,21944094,Comparative Toxicogenomics Database (CTD),Rapamycin (Sirolimus),D020123,Sirolimus,https://ctdbase.org/detail.go?type=chem&acc=D020123,7124,TNF,https://ctdbase.org/detail.go?type=gene&acc=7124,,,7124.0,TNF,10090.0,Mus musculus (house mouse),Sirolimus inhibits the reaction [TNF protein results in increased phosphorylation of MTOR protein],,,PMID:22069489,https://www.ncbi.nlm.nih.gov/pubmed/22069489,22069489,,
226,2001095,21944094,Comparative Toxicogenomics Database (CTD),Rapamycin (Sirolimus),D020123,Sirolimus,https://ctdbase.org/detail.go?type=chem&acc=D020123,7124,TNF,https://ctdbase.org/detail.go?type=gene&acc=7124,,,7124.0,TNF,10090.0,Mus musculus (house mouse),Sirolimus inhibits the reaction [TNF protein results in increased phosphorylation of RPS6 protein],,,PMID:14502240|PMID:22069489,https://www.ncbi.nlm.nih.gov/pubmed/14502240|https://www.ncbi.nlm.nih.gov/pubmed/22069489,14502240|22069489,,
